

(19) **DANMARK**

(10) **DK/EP 2872487 T3**



(12)

Oversættelse af europæisk patentskrift

Patent- og
Varemærkestyrelsen

-
- (51) Int.Cl.: **C 07 D 217/26 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2017-06-06**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2017-04-26**
- (86) Europæisk ansøgning nr.: **13740184.0**
- (86) Europæisk indleveringsdag: **2013-07-15**
- (87) Den europæiske ansøgnings publiceringsdag: **2015-05-20**
- (86) International ansøgning nr.: **US2013050538**
- (87) Internationalt publikationsnr.: **WO2014014834**
- (30) Prioritet: **2012-07-16 US 201261672191 P**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Fibrogen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA**
- (72) Opfinder: **THOMPSON, Michael D., c/o FibroGen Inc., 409 Illinois St., San Francisco, California 94158, USA**
PARK, Jung Min, c/o FibroGen Inc., 409 Illinois St., San Francisco, California 94158, USA
AREND, Michael P., c/o FibroGen Inc., 409 Illinois St., San Francisco, California 94158, USA
- (74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Rued Langgaards Vej 8, 2300 København S, Danmark**
- (54) Benævnelse: **FREM GANGSMÅDE TIL FREMSTILLING AF ISOQUINOLINFORBINDELSER**
- (56) Fremdragne publikationer:
WO-A1-2013/013609
US-A1- 2004 254 215

DESCRIPTION

CROSS REFERENCE TO RELATED APPLICATION

[0001] This application claims the benefit under 35 U.S.C. §119(e) to U. S. Application Number 61/672,191, filed July 16, 2012.

BACKGROUND

Field

[0002] The present invention relates to methods for making isoquinoline compounds and the intermediate compounds achieved thereby.

State of the Art

[0003] Isoquinoline compounds are known to be effective in the treatment and prevention of conditions and disorders associated with HIF, including anemia and tissue damage caused by ischemia and/or hypoxia (see, e.g., Robinson et al. (2008) *Gastroenterology* 134(1): 145-155; Rosenberger et al. (2008) *Nephrol Dial Transplant* 23(11):3472-3478). Specifically, the compounds and methods disclosed herein can be used as, or in the preparation of, isoquinoline compounds for inhibiting HIF hydroxylase activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF), which can then be used to treat and prevent HIF-associated conditions and disorders.

[0004] To date, a number of synthetic routes for the preparation of substituted isoquinoline compounds have been published. In 1966, Caswell et al. (*Heterocycl Chem* 1966, (3), 328-332) reported the synthesis of 4-hydroxy-3-carbomethoxy-1(2H)-isoquinoline, and the 6- and 8-methoxy substituted derivatives thereof, via the Gabriel-Coleman rearrangement of phthalimidoacetate with sodium in methanol, preferably at high temperatures (105 °C) in a sealed reaction vessel. Whereas such methods did provide an excess of one regioisomer, the substitution was dictated by the electronic nature of the substituent, not the desire of the chemist.

[0005] In 1978, Suzuki et al. (*Synthesis* 1978 (6), 461-462) reported the synthesis of 4-hydroxy-3-carbomethoxy-1(2H)-isoquinoline via the acid catalyzed ring opening and subsequent intramolecular cyclization of 4-methoxycarbonyl-1,3-oxazole, which was prepared from phthalic anhydride and methyl isocyanacetate. Suzuki et al. also reported the synthesis of the nitro substituted 4-hydroxy-3-carbomethoxy-1(2H)-isoquinoline, however, the methods disclosed therein provided a mixture of the 6- and 7-nitro isoquinoline compounds.

[0006] Weidmann et al. (U.S. Patent No. 6,093,730) reported the synthesis of various substituted isoquinoline-3-carboxamides via chromatographic separation of the 4-hydroxy-3-carbomethoxy-1(2H)-isoquinoline isomers provided by the Caswell et al. synthesis, followed by hydrolysis of the methyl ester, activation of the corresponding acid to the acid halide, and condensation with glycine methyl ester.


[0007] Other methods for the preparation of substituted isoquinoline compounds have been reported in U.S. Patent 7,629,357 and U.S. Patent 7,928,120. U.S. Patent 7,928,120 teaches the preparation of substituted cyanoisoquinoline compounds from an optionally substituted 2-methylbenzoic acid ester via reaction with a halogenating reagent to provide the corresponding 2-(halomethyl)benzoic acid ester, followed by reaction with a N-protected glycine ester, and finally cyclization/aromatization using a base and optionally an oxidizing agent. Such methods have an advantage over the documents described hereinabove in that the disclosed process affords only a single isomer of the 5-, 6-, 7-, or 8-substituted isoquinoline compounds. However, only halo and cyano substituents at the 1-position of the isoquinoline are provided. U.S. Patent 7,629,357 discloses methods for the synthesis of various substituents at the 1-position of variously substituted isoquinoline compounds, including 1-methyl isoquinoline compounds. The 1-methyl isoquinoline compounds of U.S. Patent 7,629,357 are prepared by first reacting the corresponding 1,4-dihydroxyisoquinoline compound with phosphorous oxychloride or phosphorous oxybromide to afford the 1-chloro or 1-bromoisquinoline compound, followed by methylation using either trimethylboroxine with tetrakis(triphenylphosphine)palladium or an excess of n-butyllithium followed by methyl iodide.

SUMMARY


[0008] The present invention relates to methods for synthesizing variously substituted isoquinoline compounds, and the intermediate compounds achieved thereby, safely and efficiently on a large scale. Specifically, the methods disclosed herein provide the desired 5-, 6-, 7-, or 8-substituted isoquinoline compound as a single regioisomer without the need for chromatographic separation, and do not utilize reagents such as phosphorous oxychloride, phosphorous oxybromide, n-butyllithium or trimethylboroxine, which can be unsafe and/or costly when used in a large scale.

[0009] Also provided are novel intermediate compounds achieved by the methods. The compounds disclosed herein can be used as, or in the preparation of, isoquinoline compounds for inhibiting HIF hydroxylase activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). Such compounds are useful for the treatment of disorders associated with ischemia and hypoxia, and for treatment of erythropoietin associated disorders, including *inter alia*, anemia (see, e.g., U.S. Patent No. 7,629,357).


[0010] In one aspect, the present invention is directed to a method of making a compound of formula I or a stereoisomer or mixture of stereoisomers thereof:



the method comprising contacting a compound of formula II:



with a compound of formula III:



under reaction conditions sufficient to produce a compound of formula I; wherein

Z

is O, NR¹, or S;

R¹

is selected from the group consisting of hydrogen and alkyl;

R²

is selected from the group consisting of hydrogen and alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl, and heteroaryl;

R³ and R⁴

are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halo, hydroxy, cyano, -S(O)_n-N(R⁸)-R⁸, -NR⁸C(O)NR⁸R⁸, and -X¹R⁸;

where X¹ is oxygen, -S(O)_n-, or -NR⁹-;

n is 0, 1, or 2;

each R⁸ is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclyl and substituted heterocyclyl provided that when X¹ is -SO- or -SO₂-, then R⁸ is not hydrogen; and

R⁹ is selected from the group consisting of hydrogen, alkyl, and aryl; or R³ and R⁴ together with the carbon atoms pendent thereto, form a cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

R⁵ and R⁶

are independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl and -X²R¹⁰;

where X^2 is oxygen, $-S(O)_n$, or $-NR^{13}$;


n is 0, 1, or 2;

R^{10} is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl and substituted heterocyclyl; and


R^{13} is selected from the group consisting of hydrogen, alkyl, and aryl; or when X^2 is $-NR^{13}$, then R^{10} and R^{13} , together with the nitrogen atom to which they are bound, can be joined to form a heterocyclyl or substituted heterocyclyl group; and each R^{11}

is independently selected from alkyl, benzyl or aryl, or two R^{11} together with the nitrogen atom to which they are attached form a 4-8 membered heterocyclyl or a heteroaryl.

[0011] In another aspect, the present invention is directed to a method of making a compound of formula IV or a stereoisomer or mixture of stereoisomers thereof:




the method comprising contacting a compound of formula I:




with one of the following:


- (a) a compound of formula



followed by a compound of formula




- (b) a compound of formula $R^{12}-X^3$ followed by a compound of formula



or

- (c) a compound of formula V:



under reaction conditions sufficient to produce a compound of formula IV; wherein

X^3


is halo;

R^{12}

is selected from the group consisting of alkyl, aryl, heteroaryl, and heterocyclyl, or when two R^{12} are present, two R^{12} together with the carbon atom to which they are attached form a 4-8 membered heterocyclyl; and


Z , R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^8 , R^9 , R^{10} , R^{11} , R^{13} , n, X^1 and X^2 are as defined for formula I above.

[0012] In another aspect, the present invention is directed to a method of making a compound of formula VI or a stereoisomer or mixture of stereoisomers thereof:



VI

the method comprising converting a compound of formula IV:



IV

under reaction conditions sufficient to produce a compound of formula VI; wherein


Z, R¹, R², R³, R⁴, R⁵, R⁶, R⁸, R⁹, R¹⁰, R¹¹, R¹³, n, X¹ and X²

are as defined for formula I above; and

R¹²

is selected from the group consisting of alkyl, aryl, heteroaryl, and heterocyclyl.

[0013] In another aspect, the invention is directed to a compound of formula VIII:



VIII

wherein:

Z, R¹, R², R³, R⁴, R⁵, R⁶, R⁸, R⁹, R¹⁰, R¹³, n, X¹ and X²

are as defined for formula I above;

R⁷

is -N(R¹¹)(R¹¹) or -OC(O)R¹²; and

R¹²

is selected from the group consisting of alkyl, aryl, heteroaryl, and heterocyclyl;

or a salt, ester, stereoisomer, or mixture of stereoisomers thereof;

provided that the compound is not 1-dimethylaminomethyl-4-hydroxy-7-phenylsulfanyl-isoquinoline-3-carboxylic acid butyl ester.

[0014] Additional embodiments of the invention are described throughout.

DETAILED DESCRIPTION

[0015] Before the compounds and methods are described, it is to be understood that the invention is not limited to the particular compounds, compositions, methodologies, protocols, cell lines, assays, and reagents described, as these may vary. It is also to be understood that the terminology used herein is intended to describe particular embodiments of the present invention, and is in no way intended to limit the scope of the present invention as set forth in the appended claims.

Definitions

[0016] It must be noted that as used herein, and in the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise.

[0017] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications cited herein are incorporated herein by reference in their entirety for the purpose of describing and disclosing the methodologies, reagents, and tools reported in the publications that might be used

in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

[0018] The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, molecular biology, cell biology, genetics, immunology, and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Gennaro, A.R., ed. (1990) Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Co.; Colowick, S. et al., eds., Methods In Enzymology, Academic Press, Inc.; D.M. Weir, and C.C. Blackwell, eds. (1986) Handbook of Experimental Immunology, Vols. I-IV, Blackwell Scientific Publications; Maniatis, T. et al., eds. (1989) Molecular Cloning: A Laboratory Manual, 2nd edition, Vols. I-III, Cold Spring Harbor Laboratory Press; Ausubel, F. M. et al., eds. (1999) Short Protocols in Molecular Biology, 4th edition, John Wiley & Sons; Ream et al., eds. (1998) Molecular Biology Techniques: An Intensive Laboratory Course, Academic Press; Newton & Graham eds. (1997) PCR (Introduction to Biotechniques Series), 2nd ed., Springer Verlag.

[0019] The term "alkyl" refers to saturated monovalent hydrocarbonyl groups having from 1 to 10 carbon atoms, more particularly from 1 to 5 carbon atoms, and even more particularly 1 to 3 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, *iso*-propyl, n-butyl, *t*-butyl, n-pentyl, and the like.

[0020] The term "substituted alkyl" refers to an alkyl group of from 1 to 10 carbon atoms, more particularly 1 to 5 carbon atoms, and having from 1 to 5 substituents, or 1 to 3 substituents, each of which substituents is independently selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy, aryloxyaryl, substituted aryloxyaryl, cyano, halogen, hydroxyl, nitro, oxo, thio, carboxyl, carboxyl esters, cycloalkyl, substituted cycloalkyl, thio, alkylthio, substituted alkylthio, arylthio, substituted arylthio, cycloalkylthio, substituted cycloalkylthio, heteroarylthio, substituted heteroarylthio, heterocyclithio, substituted heterocyclithio, sulfonyl, substituted sulfonyl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocycloxy, substituted heterocycloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O)₂-alkyl, -OS(O)₂-substituted alkyl, -OS(O)₂-aryl, -OS(O)₂-substituted aryl, -OS(O)₂-heteroaryl, -OS(O)₂-substituted heteroaryl, -OS(O)₂-heterocyclic, -OS(O)₂-substituted heterocyclic, and -OSO₂-NR⁴⁰R⁴⁰, -NR⁴⁰S(O)₂-NR⁴⁰-alkyl, -NR⁴⁰S(O)₂-NR⁴⁰-substituted alkyl, -NR⁴⁰S(O)₂-NR⁴⁰-aryl, -NR⁴⁰S(O)₂-NR⁴⁰-substituted aryl, -NR⁴⁰S(O)₂-NR⁴⁰-heteroaryl, -NR⁴⁰S(O)₂-NR⁴⁰-substituted heteroaryl, -NR⁴⁰S(O)₂-NR⁴⁰-heterocyclic, and -NR⁴⁰S(O)₂-NR⁴⁰-substituted heterocyclic, where each R⁴⁰ is independently selected from hydrogen or alkyl. This group is exemplified by groups such as trifluoromethyl, benzyl, pyrazol-1-ylmethyl, etc.

[0021] The term "alkoxy" refers to the group "alkyl-O-", which includes, by way of example, methoxy, ethoxy, n-propoxy, *iso*-propoxy, n-butoxy, *t*-butoxy, *sec*-butoxy, n-pentoxy, and the like.

[0022] The term "substituted alkoxy" refers to the group "substituted alkyl-O-".

[0023] The term "acyl" refers to the groups H-C(O)-, alkyl-C(O)-, substituted alkyl-C(O)-, alkenyl-C(O)-, substituted alkenyl-C(O)-, alkynyl-C(O)-, substituted alkynyl-C(O)-, cycloalkyl-C(O)-, substituted cycloalkyl-C(O)-, aryl-C(O)-, substituted aryl-C(O)-, heteroaryl-C(O)-, substituted heteroaryl-C(O), heterocyclic-C(O)-, and substituted heterocyclic-C(O)-, provided that a nitrogen atom of the heterocyclic or substituted heterocyclic is not bound to the -C(O)- group, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.

[0024] The term "aminoacyl" or "amide", or the prefix "carbamoyl," "carboxamide," "substituted carbamoyl" or "substituted carboxamide", refers to the group -C(O)NR⁴²R⁴² where each R⁴² is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; or where each R⁴² is joined to form together with the nitrogen atom a heterocyclic or substituted heterocyclic wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.

[0025] The term "acyloxy" refers to the groups alkyl-C(O)O-, substituted alkyl-C(O)O-, alkenyl-C(O)O-, substituted alkenyl-C(O)O-, alkynyl-C(O)O-, substituted alkynyl-C(O)O-, aryl-C(O)O-, substituted aryl-C(O)O-, cycloalkyl-C(O)O-, substituted cycloalkyl-C(O)O-, heteroaryl-C(O)O-, substituted heteroaryl-C(O)O-, heterocyclic-C(O)O-, and substituted heterocyclic-C(O)O-, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl,

substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.

[0026] The term "alkenyl" refers to a vinyl unsaturated monovalent hydrocarbyl group having from 2 to 6 carbon atoms, or 2 to 4 carbon atoms, and having at least 1, or from 1 to 2 sites of vinyl ($>C=C<$) unsaturation. Such groups are exemplified by vinyl (ethen-1-yl), allyl, but-3-enyl and the like. This term includes both E (trans) and Z (cis) isomers as appropriate. It also includes mixtures of both E and Z components.

[0027] The term "substituted alkenyl" refers to alkenyl groups having from 1 to 3 substituents, or 1 to 2 substituents, selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, halogen, hydroxyl, nitro, carboxyl, carboxyl esters, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic. This term includes both E (trans) and Z (cis) isomers as appropriate. It also includes mixtures of both E and Z components.

[0028] The term "alkynyl" refers to acetylenic unsaturated monovalent hydrocarbyl groups having from 2 to 6 carbon atoms, or 2 to 3 carbon atoms, and having at least 1, or from 1 to 2 sites of acetylenic ($-C\equiv C-$) unsaturation. This group is exemplified by ethyn-1-yl, propyn-1-yl, propyn-2-yl, and the like.

[0029] The term "substituted alkynyl" refers to alkynyl groups having from 1 to 3 substituents, or 1 to 2 substituents, selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, halogen, hydroxyl, nitro, carboxyl, carboxyl esters, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic. This group is exemplified by groups such as phenylethynyl, etc.

[0030] The term "amino" refers to the group $-NH_2$.

[0031] The term "substituted amino" refers to the group $-NR^{41}R^{41}$, where each R^{41} is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, sulfonyl, and substituted sulfonyl, or the R^{41} groups can be joined together with the nitrogen atom to form a heterocyclic or substituted heterocyclic ring; provided that both R^{41} groups are not hydrogen. This group is exemplified by phenylamino, methylphenylamino, and the like. This group is further exemplified by groups such as (ethanec acid-2-yl)amino, etc.

[0032] The term "acylamino" refers to the groups $-NR^{45}C(O)alkyl$, $-NR^{45}C(O)substituted\ alkyl$, $-NR^{45}C(O)cycloalkyl$, $-NR^{45}C(O)substituted\ cycloalkyl$, $-NR^{45}C(O)alkenyl$, $-NR^{45}C(O)substituted\ alkenyl$, $-NR^{45}C(O)alkynyl$, $-NR^{45}C(O)substituted\ alkynyl$, $-NR^{45}C(O)aryl$, $-NR^{45}C(O)substituted\ aryl$, $-NR^{45}C(O)heteroaryl$, $-NR^{45}C(O)substituted\ heteroaryl$, $-NR^{45}C(O)heterocyclic$, and $-NR^{45}C(O)substituted\ heterocyclic$ where R^{45} is hydrogen or alkyl, and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are defined herein.

[0033] The term "oxycarbonylamino" refers to the groups $-NR^{46}C(O)O-alkyl$, $-NR^{46}C(O)O-substituted\ alkyl$, $-NR^{46}C(O)O-alkenyl$, $-NR^{46}C(O)O-substituted\ alkenyl$, $-NR^{46}C(O)O-alkynyl$, $-NR^{46}C(O)O-substituted\ alkynyl$, $-NR^{46}C(O)O-cycloalkyl$, $-NR^{46}C(O)O-substituted\ cycloalkyl$, $-NR^{46}C(O)O-aryl$, $-NR^{46}C(O)O-substituted\ aryl$, $-NR^{46}C(O)O-heteroaryl$, $-NR^{46}C(O)O-substituted\ heteroaryl$, $-NR^{46}C(O)O-heterocyclic$, and $-NR^{46}C(O)O-substituted\ heterocyclic$ where R^{46} is hydrogen or alkyl, and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.

[0034] The term "oxythiocarbonylamino" refers to the groups $-NR^{46}C(S)O-alkyl$, $-NR^{46}C(S)O-substituted\ alkyl$, $-NR^{46}C(S)O-alkenyl$, $-NR^{46}C(S)O-substituted\ alkenyl$, $-NR^{46}C(S)O-alkynyl$, $-NR^{46}C(S)O-substituted\ alkynyl$, $-NR^{46}C(S)O-cycloalkyl$, $-NR^{46}C(S)O-substituted\ cycloalkyl$, $-NR^{46}C(S)O-aryl$, $-NR^{46}C(S)O-substituted\ aryl$, $-NR^{46}C(S)O-heteroaryl$, $-NR^{46}C(S)O-substituted\ heteroaryl$, $-NR^{46}C(S)O-heterocyclic$, and $-NR^{46}C(S)O-substituted\ heterocyclic$ where R^{46} is hydrogen or alkyl, and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.

[0035] The term "aminocarbonyloxy," or the prefix "carbamoyloxy" or "substituted carbamoyloxy," refers to the groups -

OC(O)NR⁴⁷R⁴⁷ where each R⁴⁷ is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; or where each R⁴⁷ is joined to form, together with the nitrogen atom, a heterocyclic or substituted heterocyclic, and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.

[0036] The term "aminocarbonylamino" refers to the group -NR⁴⁹C(O)N(R⁴⁹)₂ where each R⁴⁹ is independently selected from the group consisting of hydrogen and alkyl.

[0037] The term "aminothiocarbonylamino" refers to the group -NR⁴⁹C(S)N(R⁴⁹)₂ where each R⁴⁹ is independently selected from the group consisting of hydrogen and alkyl.

[0038] The term "aryl" or "Ar" refers to a monovalent aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings may or may not be aromatic (e.g., 2-benzoxazolinone, 2H-1,4-benzoxazin-3(4H)-one-7-yl, and the like) provided that the point of attachment is the aryl group. Preferred aryls include phenyl and naphthyl.

[0039] The term "substituted aryl" refers to aryl groups, as defined herein, which are substituted with from 1 to 4, particularly 1 to 3, substituents selected from the group consisting of hydroxy, acyl, acylamino, acyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amidino (-C(=NH)-amino or substituted amino), amino, substituted amino, aminoacyl, aminocarbonyloxy, aminocarbonylamino, aminothiocarbonylamino, aryl, substituted aryl, aryloxy, substituted aryloxy, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocycloxy, substituted heterocycloxy, carboxyl, carboxyl esters, cyano, thio, alkylthio, substituted alkylthio, arylthio, substituted arylthio, heteroarylthio, substituted heteroarylthio, cycloalkylthio, substituted cycloalkylthio, heterocyclithio, substituted heterocyclithio, cycloalkyl, substituted cycloalkyl, guanidino (-NH-C(=NH)-amino or substituted amino), halo, nitro, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, oxycarbonylamino, oxythiocarbonylamino, sulfonyl, substituted sulfonyl, -OS(O)₂-alkyl, -OS(O)₂-substituted alkyl, -OS(O)₂-aryl, -OS(O)₂-substituted aryl, -OS(O)₂-heteroaryl, -OS(O)₂-substituted heteroaryl, -OS(O)₂-heterocyclic, -OS(O)₂-substituted heterocyclic, and -OSO₂-NR⁵¹R⁵¹, -NR⁵¹S(O)₂-NR⁵¹-alkyl, -NR⁵¹S(O)₂-NR⁵¹-substituted alkyl, -NR⁵¹S(O)₂-NR⁵¹-aryl, -NR⁵¹S(O)₂-NR⁵¹-substituted aryl, -NR⁵¹S(O)-NR⁵¹-heteroaryl, -NR⁵¹S(O)-NR⁵¹-substituted heteroaryl, -NR⁵¹S(O)₂-NR⁵¹-heterocyclic, -NR⁵¹S(O)₂-NR⁵¹-substituted heterocyclic, where each R⁵¹ is independently selected from hydrogen or alkyl, wherein each of the terms is as defined herein. This group is exemplified by groups such as 4-fluorophenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-*t*-butylphenyl, 4-trifluoromethylphenyl, 2-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-chloro-6-fluorophenyl, 2,4-dichlorophenyl, 3,5-difluorophenyl, 4-methoxyphenyl, 3-cyanophenyl, 4-cyanophenyl, 4-phenoxyphenyl, 4-methanesulfonylphenyl, biphenyl-4-yl, etc.

[0040] The term "aryloxy" refers to the group aryl-O- that includes, by way of example, phenoxy, naphthoxy, and the like.

[0041] The term "substituted aryloxy" refers to substituted aryl-O- groups.

[0042] The term "aryloxyaryl" refers to the group -aryl-O-aryl.

[0043] The term "substituted aryloxyaryl" refers to aryloxyaryl groups substituted with from 1 to 3 substituents on either or both aryl rings as defined above for substituted aryl.

[0044] The term "carboxyl" refers to -COOH or salts thereof.

[0045] The term "carboxyl ester" refers to the groups -C(O)O-alkyl, -C(O)O-substituted alkyl, -C(O)O-alkenyl, -C(O)O-substituted alkenyl, -C(O)O-alkynyl, -C(O)O-substituted alkynyl, -C(O)O-cycloalkyl, -C(O)O-substituted cycloalkyl, -C(O)O-aryl, -C(O)O-substituted aryl, -C(O)O-heteroaryl, -C(O)O-substituted heteroaryl, -C(O)O-heterocyclic, and -C(O)O-substituted heterocyclic.

[0046] The term "cyano" refers to the group -CN.

[0047] The term "cycloalkyl" refers to a saturated or an unsaturated but nonaromatic cyclic alkyl group of from 3 to 10, 3 to 8 or 3 to 6 carbon atoms having single or multiple cyclic rings including, by way of example, adamantyl, cyclopropyl, cyclobutyl,

cyclopentyl, cyclooctyl, cyclohexenyl, and the like.

[0048] The term "substituted cycloalkyl" refers to a cycloalkyl group, having from 1 to 5 substituents selected from the group consisting of oxo (=O), thioxo (=S), alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, halogen, hydroxy, nitro, carboxyl, carboxyl esters, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.

[0049] The term "cycloalkoxy" refers to -O-cycloalkyl groups.

[0050] The term "substituted cycloalkoxy" refers to -O-substituted cycloalkyl groups.

[0051] The term "halo" or "halogen" refers to fluoro, chloro, bromo, or iodo.

[0052] The term "hydroxy" or "hydroxyl" refers to the group -OH.

[0053] The term "heteroaryl" refers to an aromatic ring of from 1 to 15 carbon atoms, or from 1 to 10 carbon atoms, and 1 to 4 heteroatoms within the ring selected from the group consisting of oxygen, nitrogen, and sulfur. Such heteroaryl groups can have a single ring (e.g., pyridinyl, furyl, or thienyl) or multiple condensed rings (e.g., indolizinyl or benzothienyl) provided the point of attachment is through a ring containing the heteroatom and that ring is aromatic. The nitrogen and/or sulfur ring atoms can optionally be oxidized to provide for the N-oxide or the sulfoxide, and sulfone derivatives. Examples of heteroaryls include but are not limited to, pyridinyl, pyrimidinyl, pyrrolyl, pyrazolyl, indolyl, thiophenyl, thienyl, and furyl.

[0054] The term "substituted heteroaryl" refers to heteroaryl groups that are substituted with from 1 to 3 substituents selected from the same group of substituents defined for substituted aryl. This group is exemplified by groups such as 5-fluoro-pyridin-3-yl, 1-benzyl-1H-[1,2,3]triazol-4-yl, 5-bromo-furan-2-yl, trifluoromethyl-2H-pyrazol-3-yl, etc.

[0055] The term "heteroaryloxy" refers to the group -O-heteroaryl and "substituted heteroaryloxy" refers to the group -O-substituted heteroaryl.

[0056] The terms "heterocyclyl" and "heterocyclic" are used interchangeably herein. As used herein, the terms refer to a saturated or unsaturated (but not aromatic) group having a single ring or multiple condensed rings, from 1 to 10 carbon atoms, and from 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur or oxygen within the ring wherein, in fused ring systems, one or more of the rings can be aryl or heteroaryl provided that the point of attachment is at the heterocycle. The nitrogen and/or sulfur ring atoms can optionally be oxidized to provide for the N-oxide or the sulfoxide, and sulfone derivatives.

[0057] The term "substituted heterocyclyl" or "substituted heterocyclic" refers to heterocycle groups that are substituted with from 1 to 3 of the same substituents as defined for substituted cycloalkyl.

[0058] Examples of heterocycles and heteroaryls include, but are not limited to, azetidiny, pyrrolyl, imidazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, dihydroindolyl, indazolyl, purinyl, quinolizinyl, isoquinolinyl, quinolinyl, phthalazinyl, naphthylpyridinyl, quinoxalyl, quinazolinyl, cinnolinyl, pteridinyl, carbazolyl, carbolinyl, phenanthridinyl, acridinyl, phenanthrolinyl, isothiazolyl, phenazinyl, isoxazolyl, phenoxazinyl, phenothiazinyl, imidazolidinyl, imidazolyl, piperidinyl, piperazinyl, indolinyl, phthalimidyl, 1,2,3,4-tetrahydroisoquinolinyl, 4,5,6,7-tetrahydrobenzo[b]thiophenyl, thiazolyl, thiazolidinyl, thiophenyl, benzo[b]thiophenyl, morpholinyl, thiomorpholinyl (also referred to as thiamorpholinyl), piperidinyl, pyrrolidinyl, tetrahydrofuranly, and the like.

[0059] The term "nitro" refers to the group -NO₂.

[0060] The term "oxo" refers to the atom (=O) or to the atom (-O⁻).

[0061] The term "sulfonyl" refers to the group -S(O)₂H. The term "substituted sulfonyl" refers to the group -SO₂-alkyl, -SO₂-substituted alkyl, -SO₂-alkenyl, -SO₂-substituted alkenyl, -SO₂-alkynyl, -SO₂-substituted alkynyl, -SO₂-cycloalkyl, -SO₂-substituted cycloalkyl, -SO₂-cycloalkenyl, -SO₂-substituted cycloalkenyl, -SO₂-aryl, -SO₂-substituted aryl, -SO₂-heteroaryl, -SO₂-substituted heteroaryl, -SO₂-heterocyclic, -SO₂-substituted heterocyclic, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl and substituted heterocyclyl are as defined herein. Substituted sulfonyl includes groups such as methyl-SO₂-, phenyl-SO₂-, and 4-methylphenyl-SO₂-.

[0062] The term "heterocycloxy" refers to the group -O-heterocyclic, and "substituted heterocycloxy" refers to the group -O-substituted heterocyclic.

[0063] The term "thio" or "mercapto" refers to the group -SH.

[0064] The term "alkylsulfanyl," "alkylthio," or "thioether" refers to the groups -S-alkyl where alkyl is as defined above.

[0065] The term "substituted alkylthio," "substituted alkylsulfanyl," or "substituted alkylthio" refers to the group -S-substituted alkyl where substituted alkyl is as defined above.

[0066] The term "cycloalkylthio" or "cycloalkylsulfanyl" refers to the groups -S-cycloalkyl where cycloalkyl is as defined above.

[0067] The term "substituted cycloalkylthio" refers to the group -S-substituted cycloalkyl where substituted cycloalkyl is as defined above.

[0068] The term "arylthio" or "arylsulfanyl" refers to the group -S-aryl, and "substituted arylthio" refers to the group -S-substituted aryl where aryl and substituted aryl are as defined above.

[0069] The term "heteroarylthio" or "heteroarylsulfanyl" refers to the group -S-heteroaryl, and "substituted heteroarylthio" refers to the group -S-substituted heteroaryl where heteroaryl and substituted heteroaryl are as defined above.

[0070] The term "heterocyclicthio" or "heterocyclicsulfanyl" refers to the group -S-heterocyclic, and "substituted heterocyclicthio" refers to the group -S-substituted heterocyclic where heterocyclic, and substituted heterocyclic are as defined above.

[0071] The term "ester" refers to compounds as disclosed herein that include the group -COOR⁵⁴ where R⁵⁴ is alkyl, or substituted alkyl.

[0072] The term "amine" refers to an organic compound that contains a basic nitrogen atom with a lone pair of electrons. Amines are derivatives of ammonia, wherein one or more hydrogen atoms have been replaced by a substituent such as an alkyl or aryl group. The basic nitrogen atom may also be part of a heterocyclic or heteroaryl ring.

[0073] It is understood that in all substituted groups defined above, polymers arrived at by defining substituents with further substituents to themselves (e.g., substituted aryl having a substituted aryl group as a substituent which is itself substituted with a substituted aryl group, etc.) are not intended for inclusion herein. Also not included are infinite numbers of substituents, whether the substituents are the same or different. In such cases, the maximum number of such substituents is three. Each of the above definitions is thus constrained by a limitation that, for example, substituted aryl groups are limited to -substituted aryl-(substituted aryl)-substituted aryl.

[0074] Similarly, it is understood that the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluoro groups or a hydroxyl group alpha to ethenyl or acetylenic unsaturation). Such impermissible substitution patterns are well known to the skilled artisan.

[0075] The term compound and molecule are used interchangeably. Other forms contemplated by the invention when the word "molecule" or "compound" is employed are salts, prodrugs, solvates, tautomers, stereoisomers and mixtures of stereoisomers. In some embodiments, the salts are pharmaceutically acceptable salts.

[0076] The term "pharmaceutically acceptable" refers to those properties and/or substances that are acceptable to a patient (e.g., human patient) from a toxicological and/or safety point of view.

[0077] The term "salt" means salts of the compounds of the present disclosure, which may be prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present disclosure contain relatively acidic functionalities (e.g., -COOH group), base addition salts can be obtained by contacting the compound (e.g., neutral form of such compound) with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include lithium, sodium, potassium, calcium, ammonium, organic amino, magnesium and aluminum salts and the like. When compounds of the present disclosure contain relatively basic functionalities (e.g., amines), acid addition salts can be obtained, e.g., by contacting the compound (e.g., neutral form of such

compound) with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, diphosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic and the like, as well as the salts derived from relatively nontoxic organic acids like formic, acetic, propionic, isobutyric, malic, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, 2-hydroxyethylsulfonic, salicylic, stearic and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galacturonic acids and the like (see, for example, Berge et al., *Journal of Pharmaceutical Science*, 1977, 66: 1-19). Certain specific compounds of the present disclosure contain both, basic and acidic, functionalities that allow the compounds to be converted into either base or acid addition salts. In addition, the counterion can be exchanged using conventional methods known in the art.

[0078] The neutral forms of the compounds can be regenerated, for example, by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound can differ from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present disclosure.

[0079] When a compound includes a negatively charged oxygen atom "O⁻", e.g., in "-COO⁻", then the formula is meant to optionally include a proton or an organic or inorganic cationic counterion (e.g., Na⁺). In one example, the resulting salt form of the compound is pharmaceutically acceptable. Further, when a compound of the present disclosure includes an acidic group, such as a carboxylic acid group, e.g., written as the substituent "-COOH", "-CO₂H" or "-C(O)₂H", then the formula is meant to optionally include the corresponding "de-protonated" form of that acidic group, e.g., "-COO⁻", "-CO₂⁻" or "-C(O)₂⁻", respectively.

[0080] Likewise, when a compound includes a positively charged nitrogen atom "N⁺", then the formula is meant to optionally include an organic or inorganic anionic counterion (e.g., Cl⁻). In one example, the resulting salt form of the compound is pharmaceutically acceptable. Further, when a compound of the present disclosure includes a basic group, such as an amine, then the formula is meant to optionally include the corresponding "protonated" form of that basic group, e.g., "NH⁺".

[0081] Compounds of the present disclosure can exist in all tautomeric forms and, therefore, all tautomeric forms and mixtures of tautomers are included in the compounds disclosed herein.

[0082] Compounds of the present disclosure can also exist in particular geometric or stereoisomeric forms. The present disclosure contemplates all such compounds, including *cis*- and *trans*-isomers, (-)- and (+)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, as falling within the scope of the present disclosure. Additional asymmetric carbon atoms can be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this disclosure. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.

[0083] Optically active (*R*)- and (*S*)-isomers and *d* and *l* isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. Resolution of the racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent; chromatography, using, for example a chiral HPLC column; or derivatizing the racemic mixture with a resolving reagent to generate diastereomers, separating the diastereomers via chromatography, and removing the resolving agent to generate the original compound in enantiomerically enriched form. Any of the above procedures can be repeated to increase the enantiomeric purity of a compound. If, for instance, a particular enantiomer of a compound of the present disclosure is desired, it can be prepared by asymmetric synthesis, or by derivatization with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as an amino group, or an acidic functional group, such as a carboxyl group, diastereomeric salts can be formed with an appropriate optically active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means known in the art, and subsequent recovery of the pure enantiomers. In addition, separation of enantiomers and diastereomers is frequently accomplished using chromatography employing chiral, stationary phases, optionally in combination with chemical derivatization (e.g., formation of carbamates from amines).

[0084] The term "reaction conditions" is intended to refer to the physical and/or environmental conditions under which a chemical reaction proceeds. Examples of reaction conditions include, but are not limited to, one or more of following: reaction temperature, solvent, pH, pressure, reaction time, mole ratio of reactants, the presence of a base or acid, or catalyst, etc. Reaction conditions

may be named after the particular chemical reaction in which the conditions are employed, such as, coupling conditions, hydrogenation conditions, acylation conditions, reduction conditions, etc. Reaction conditions for most reactions are generally known to those skilled in the art or can be readily obtained from the literature. It is also contemplated that the reaction conditions can include reagents in addition to those listed in the specific reaction.

[0085] The term "amino-protecting group" refers to those organic groups intended to protect the nitrogen atom against undesirable reactions during synthetic procedures and includes, but is not limited to, silyl ethers, such as 2-(trimethylsilyl)ethoxymethyl (SEM) ether, or alkoxymethyl ethers, such as methoxymethyl (MOM) ether, *tert*-butoxymethyl (BUM) ether, benzyloxymethyl (BOM) ether or methoxyethoxymethyl (MEM) ether. Additional protecting groups include, *tert*-butyl, acetyl, benzyl, benzyloxycarbonyl (carbobenzyloxy, CBZ), *p*-methoxybenzyloxycarbonyl, *p*-nitrobenzyloxycarbonyl, *tert*-butoxycarbonyl (BOC), trifluoroacetyl, and the like.

[0086] Certain protecting groups may be preferred over others due to their convenience or relative ease of removal, or due to their stereospecific effects in subsequent steps of the process. Additional suitable amino protecting groups are taught in T. W. Greene and P.G. M. Wuts, *Protecting Groups in Organic Synthesis*, Third Edition, Wiley, New York, 1999, and references cited therein which are all incorporated by reference in its entirety.

[0087] The term "anhydrous reaction conditions" is intended to refer to reaction conditions wherein water is excluded. Such conditions are known to one of skill in the art, and typically comprise one or more of dry or distilled solvents and reagents, dried reaction vessels, and/or the presence of a drying agent, such as activated molecular sieves, magnesium sulfate, sodium sulfate, etc.

[0088] The term "hydrogenation conditions" or "hydrogenation reaction conditions" is intended to refer to suitable conditions and catalysts for forming one or more new C-H bonds. Hydrogenation conditions or hydrogenation reaction conditions typically include a catalyst, such as those based on platinum group metals (platinum, palladium, rhodium, and ruthenium) (e.g. Pd/C or PtO₂).

[0089] The term "inert atmosphere" is intended to refer to an atmosphere comprising a gas which does not react with the reactants and reagents during the desired reaction process. Typically an inert atmosphere excludes oxygen and/or moisture. Exemplary gases include nitrogen and argon.

[0090] The term "under pressure" is intended to refer to reaction conditions which are conducted under a pressure of greater than 1 atmosphere. Such reactions can be carried out in a par hydrogenator or in an otherwise sealed reaction vessel (i.e. a screw capped flask) where the reaction is performed under heat such that the solvent vapors increase the pressure within the reaction vessel.

[0091] The term "acid" is intended to refer to a chemical species that can either donate a proton or accept a pair of electrons from another species. Examples of acids include organic acids, such as carboxylic acids (e.g. lactic acid, acetic acid, formic acid, citric acid, oxalic acid, uric acid, etc.) and sulfonic acids (e.g., methanesulfonic acid, *p*-toluenesulfonic acid), mineral acids (e.g. hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, boric acid, hydrofluoric acid, hydrobromic acid), Lewis acids, etc. The term "Lewis acid" is used herein refers to a molecule or ion that can combine with another molecule or ion by forming a covalent bond with two electrons from the second molecule or ion. For use in the process of the invention, a Lewis acid is considered as an electron deficient species that can accept a pair of electrons. Examples of Lewis acids that can be used in the present invention are cations of metals and their complexes including magnesium, calcium, aluminum, zinc, titanium, chromium, copper, boron, tin, mercury, iron, manganese, cadmium, gallium and barium. Their complex may include hydroxides, alkyls, alkoxides, halides and organic acid ligands such as acetates. Preferred examples of Lewis acids useful in the instant process are titanium alkoxides, particularly Ti(OEt)₄ which additionally possesses dehydrating properties.

[0092] The term "base" is intended to refer to a chemical species that are proton acceptors. Suitable bases for use in the present invention include inorganic or organic bases. Examples of inorganic base include, but are not limited to, potassium hydroxide (KOH), barium hydroxide (Ba(OH)₂), caesium hydroxide (CsOH), sodium hydroxide (NaOH), strontium hydroxide (Sr(OH)₂), calcium hydroxide (Ca(OH)₂), lithium hydroxide (LiOH), rubidium hydroxide (RbOH), and magnesium hydroxide (Mg(OH)₂). Organic bases can be neutral or negatively charged compounds which typically contain nitrogen atoms such as amines and nitrogen-containing heterocyclic compounds. Examples of neutral nitrogen containing organic bases include ammonia, pyridine, methyl amine, imidazole, 2,2,6,6-tetramethylpiperidine, 4-(dimethylamino)pyridine and the like. Examples of negatively charged organic bases includes alkyl lithium reagents, lithium dialkylamides, lithium alkylloxides, alkylmagnesium halides and the like.

Methods

[0093] The present invention provides methods for synthesizing variously substituted isoquinoline compounds, and the intermediate compounds achieved thereby. The methods enable the isoquinoline compounds to be prepared safely and efficiently on a large scale, such as would be desired for the commercial production of such compounds.

[0094] One advantage of the present methods over those disclosed previously is that the methods disclosed herein do not require the separation of regioisomers. For example, the methods disclosed in Suzuki et al. (*supra*), Weidmann et al. (*supra*), and U.S. Patent No. 7,629,357, provide a regioisomeric mixture of the 5- and 8-substituted isoquinoline compounds or the 6- and 7-substituted isoquinoline compounds, which are then separated using standard chromatographic methods. However, such separations are undesirable as the maximum theoretical yield for the step can be only 50%.

[0095] Another advantage of the present methods over those disclosed previously, is that the methods disclosed herein do not utilize hazardous and/or costly reagents. Specifically, the methods disclosed herein avoid the halogenation step and thus avoid reagents such as phosphorous oxychloride and phosphorous oxybromide (see, for example, previously disclosed synthesis in U.S. Patent No. 7,323,475 described in Scheme E herein, **E-400 to E-500**). These reagents are extremely destructive to tissue of the mucous membranes, upper respiratory tract, eyes, and skin. In addition, the methods avoid reagents such as n-butyllithium and trimethylboroxine, both of which require special handling procedures as they are very reactive to moisture. Therefore, the methods disclosed herein are advantageous over such methods which utilize undesirable reagents.


[0096] The methods of this invention employ starting compounds which can be prepared from readily available starting materials or the compounds as disclosed herein using, for example, the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.

[0097] Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and G. M. Wuts (1999) *Protecting Groups in Organic Synthesis*, 3rd Edition, Wiley, New York, and references cited therein.


[0098] Furthermore, the methods of this invention may employ compounds which contain one or more chiral centers. Accordingly, if desired, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this invention, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents, and the like.

[0099] The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, U.S.A), Bachem (Torrance, California, U.S.A), Emka-Chemce or Sigma (St. Louis, Missouri, U.S.A). Others may be prepared by procedures, or obvious modifications thereof, described in standard reference texts such as Fieser and Fieser's *Reagents for Organic Synthesis*, Volumes 1-15 (John Wiley, and Sons, 1991), *Rodd's Chemistry of Carbon Compounds*, Volumes 1-5, and Supplementals (Elsevier Science Publishers, 1989), *Organic Reactions*, Volumes 1-40 (John Wiley, and Sons, 1991), *March's Advanced Organic Chemistry*, (John Wiley, and Sons, 5th Edition, 2001), and *Larock's Comprehensive Organic Transformations* (VCH Publishers Inc., 1989).


[0100] In one aspect, the present invention is directed to a method of making a compound of formula I or a stereoisomer or mixture of stereoisomers thereof:



the method comprising contacting a compound of formula II:



with a compound of formula III:



under reaction conditions sufficient to produce a compound of formula I; wherein

Z

is O, NR¹, or S;

R¹

is selected from the group consisting of hydrogen and alkyl;

R²

is selected from the group consisting of hydrogen and alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl, and heteroaryl;

R³ and R⁴

are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halo, hydroxy, cyano, -S(O)_n-, N(R⁸)-R⁸, -NR⁸C(O)NR⁸R⁸, and -X¹R⁸;

where X¹ is oxygen, -S(O)_n-, or -NR⁹-;

n is 0, 1, or 2;

each R⁸ is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclyl and substituted heterocyclyl provided that when X¹ is -SO- or -SO₂-, then R⁸ is not hydrogen; and

R⁹ is selected from the group consisting of hydrogen, alkyl, and aryl; or R³ and R⁴ together with the carbon atoms pendent thereto, form a cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

R⁵ and R⁶

are independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl and -X²R¹⁰;

where X² is oxygen, -S(O)_n-, or -NR¹³-;

n is 0, 1, or 2;


R¹⁰ is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl and substituted heterocyclyl; and

R¹³ is selected from the group consisting of hydrogen, alkyl, and aryl; or when X² is -NR¹³-, then R¹⁰ and R¹³, together with the nitrogen atom to which they are bound, can be joined to form a heterocyclyl or substituted heterocyclyl group; and


each R¹¹

is independently selected from alkyl, benzyl and aryl, or two R¹¹ together with the nitrogen atom to which they are attached form a 4-8 membered heterocyclyl or a heteroaryl.


[0101] In particular embodiments, the present invention is directed to a method of making a compound of formula IA or a stereoisomer or mixture of stereoisomers thereof:



comprising contacting a compound of formula IIA:



with a compound of formula III:



under reaction conditions sufficient to produce a compound of formula IA; wherein

R², R³, R⁴, R⁵, R⁶, R⁸, R⁹, R¹⁰, R¹¹, R¹³, n, X¹ and X² are as defined for formula I above.

[0102] The reaction may be carried out in glacial acetic acid or a polar aprotic solvent such as dioxane, tetrahydrofuran (THF), dimethylformamide (DMF), or dimethylacetamide (DMAc) to produce compounds of formula I or IA with or without an acid catalyst. In certain embodiments, the reaction conditions comprise an acid. The acid may be selected from, e.g., acetic acid, trifluoroacetic acid, sulfuric acid, hydrochloric acid, or an acidic ion exchange resin. In various embodiments, about 0.1-14 molar equivalents of acid may be used. In some embodiments, the acid is glacial acetic acid. In some embodiments, at least about 2 molar equivalents of glacial acetic acid are used. In particular embodiments, about 7 to about 8 molar equivalents of glacial acetic acid are used.

[0103] In certain embodiments, the reaction is conducted under an inert atmosphere, such as an argon or nitrogen atmosphere. In some embodiments, the reaction is conducted under a nitrogen atmosphere.

[0104] In certain embodiments, the reaction conditions are anhydrous reaction conditions. Such conditions typically include drying reagents (e.g. molecular sieves), conducting the reaction under an inert atmosphere, and the like. Such methods are well known in the art.

[0105] In certain embodiments, the reaction is conducted at a temperature between room temperature (ca 25 °C) and 110 °C, and at a pressure from 0 to 60 psi. In some embodiments, the reaction is conducted at an elevated temperature, i.e., at a temperature greater than about 30 °C. For example, the temperature can range from about 50 °C to about 60 °C.

[0106] In certain embodiments, from about 1.1 to about 1.5 molar equivalents of the compound of formula III is used.


[0107] In certain embodiments, the reaction is conducted in glacial acetic acid, and at a temperature range from about 50 °C to about 60 °C; and R¹¹ of a compound of formula III is C₁ to C₄ alkyl.

[0108] In certain embodiments, the reaction is conducted in glacial acetic acid, under a nitrogen atmosphere, and at a temperature range from about 50 °C to about 60 °C; and R¹¹ of a compound of formula III is C₁ to C₄ alkyl.


[0109] In certain embodiments, the reaction is conducted in about 7 to about 8 molar equivalents of glacial acetic acid, at a temperature range from about 50 °C to about 60 °C, and about 1.1 to about 1.5 molar equivalents of a compound of formula III is used where R¹¹ is C₁ to C₄ alkyl.

[0110] In certain embodiments, the reaction is conducted in about 7 to about 8 molar equivalents of glacial acetic acid, under a nitrogen atmosphere, at a temperature range from about 50 °C to about 60 °C, and about 1.1 to about 1.5 molar equivalents of a compound of formula III is used where R¹¹ is C₁ to C₄ alkyl.


[0111] In certain embodiments, R¹¹ of a compound of formula III is C₁ to C₄ alkyl. In certain embodiments, the compound of formula III comprises a compound of formula IIIA:



[0112] In another aspect, the present invention is directed to a method of making a compound of formula IV or a stereoisomer or mixture of stereoisomers thereof:



the method comprising contacting a compound of formula I:



with one of the following:

1. (a) a compound of formula



followed by a compound of formula




2. (b) a compound of formula $R^{12}-X^3$ followed by a compound of formula



or

3. (c) a compound of formula V:



under reaction conditions sufficient to produce a compound of formula IV; wherein

X^3

is halo;


R^{12}

is selected from the group consisting of alkyl, aryl, heteroaryl, and heterocyclyl, or when two R^{12} are present, two R^{12} together with the carbon atom to which they are attached form a 4-8 membered heterocyclyl; and


Z , R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^8 , R^9 , R^{10} , R^{11} , R^{13} , n , X^1 and X^2

are as defined for formula I above.


[0113] In one embodiment, the present invention is directed to a method of making a compound of formula IVA or a stereoisomer or mixture of stereoisomers thereof:



comprising contacting a compound of formula IA:



with a compound of formula V:



under reaction conditions sufficient to produce a compound of formula IVA; wherein

R^{12}

is selected from the group consisting of alkyl, aryl, heteroaryl, and heterocyclyl, or when two R^{12} are present, two R^{12} together with the carbon atom to which they are attached form a 4-8 membered heterocyclyl; and

$R^2, R^3, R^4, R^5, R^6, R^8, R^9, R^{10}, R^{11}, R^{13}, n, X^1$ and X^2 are as defined for formula I above.

[0114] The reaction may be carried out in glacial acetic acid or a polar aprotic solvent such as dioxane, THF, DMF, or DMAc with or without an acid catalyst. In certain embodiments, the reaction conditions comprise an acid. The acid may be selected from, e.g., acetic acid, trifluoroacetic acid, sulfuric acid, hydrochloric acid, or an acidic ion exchange resin. In various embodiments, about 0.1-14 molar equivalents of acid may be used. In some embodiments, the acid is glacial acetic acid. In some embodiments, at least about 2 molar equivalents of glacial acetic acid are used. In particular embodiments, about 7 to about 8 molar equivalents of glacial acetic acid are used.

[0115] In certain embodiments, the reaction is conducted under an inert atmosphere, such as an argon or nitrogen atmosphere. In some embodiments, the reaction is conducted under a nitrogen atmosphere.

[0116] In certain embodiments, the reaction conditions are anhydrous reaction conditions. Such conditions typically include drying reagents (e.g. molecular sieves), conducting the reaction under an inert atmosphere, and the like. Such methods are well known in the art.

[0117] In certain embodiments, the reaction is conducted at an elevated temperature, i.e., at a temperature greater than about 30 °C. For example, in certain embodiments, the temperature is about 100 °C.

[0118] In various embodiments, from about 1 to about 4 molar equivalents of the compound of formula V is used. In particular embodiments, where the compound of formula I or IA is isolated prior to reaction, about 1 molar equivalent of the compound of formula V is used. In other embodiments, from about 2 to about 3 molar equivalents of the compound of formula V is used. In certain embodiments, the compound of formula V comprises acetic anhydride.

[0119] In certain embodiments, the reaction conditions comprise a compound of formula V where R^{12} is C_1 to C_4 alkyl; and the reaction is conducted at an elevated temperature.


[0120] In certain embodiments, the reaction conditions comprise a compound of formula V where R^{12} is C_1 to C_4 alkyl; and the reaction is conducted at a temperature of about 100°C.

[0121] In certain embodiments the reaction conditions comprise a compound of formula V where R^{12} is C_1 to C_4 alkyl; and the reaction is conducted under an inert atmosphere, and at an elevated temperature. In certain embodiments, further a compound of formula V is acetic anhydride.

[0122] In certain embodiments, the reaction conditions comprise about 2 to about 3 molar equivalents of a compound of formula V where R^{12} is C_1 to C_4 alkyl; and the reaction is conducted at a temperature of about 100 °C. In certain embodiments, further a compound of formula V is acetic anhydride.

[0123] In certain embodiments, the reaction conditions comprise about 2 to about 3 molar equivalents of a compound of formula V where R^{12} is C_1 to C_4 alkyl; and the reaction is conducted under a nitrogen atmosphere, and at a temperature of about 100 °C. In certain embodiments, further a compound of formula V is acetic anhydride.

[0124] In certain embodiments, the reaction conditions further comprise converting a compound of formula VII to a compound of formula IV:




under reaction conditions sufficient to produce a compound of formula IV;

wherein Z, R¹, R², R³, R⁴, R⁵, R⁶, R⁸, R⁹, R¹⁰, R¹³, n, X¹ and X² are as defined for formula I above; and

R¹² is selected from the group consisting of alkyl, aryl, heteroaryl, and heterocyclyl.

[0125] In certain embodiments, the reaction conditions further comprise converting a compound of formula VIIA to a compound of formula IVA:



under reaction conditions sufficient to produce a compound of formula IVA;

wherein R², R³, R⁴, R⁵, R⁶, R⁸, R⁹, R¹⁰, R¹³, n, X¹ and X² are as defined for formula I above; and


R¹² is selected from the group consisting of alkyl, aryl, heteroaryl, and heterocyclyl.

[0126] In certain embodiments, the reaction is conducted in a solvent selected from dichloromethane, ethyl acetate or THF. In particular embodiments, the solvent is dichloromethane.


[0127] In certain embodiments, the reaction conditions comprise an amine. In some embodiments, the amine is morpholine. In certain embodiments, the reaction is conducted at a temperature from about 0 °C to about 10 °C.

[0128] In certain embodiments, the reaction conditions comprise morpholine; and the reaction is conducted in dichloromethane, and at a temperature from about 0 °C to about 10 °C.

[0129] In another aspect, the present invention is directed to a method of making a compound of formula VI or a stereoisomer or mixture of stereoisomers thereof:



the method comprising converting a compound of formula IV:




under reaction conditions sufficient to produce a compound of formula VI;

wherein Z, R¹, R², R³, R⁴, R⁵, R⁶, R⁸, R⁹, R¹⁰, R¹³, n, X¹ and X² are as defined for formula I above; and


R¹² is selected from the group consisting of alkyl, aryl, heteroaryl, and heterocyclyl.

[0130] In another embodiment, the present invention is directed to a method of making a compound of formula VIA or a stereoisomer or mixture of stereoisomers thereof:



VIA

comprising converting a compound of formula IVA:



IVA

under reaction conditions sufficient to produce a compound of formula VIA;

wherein R², R³, R⁴, R⁵, R⁶, R⁸, R⁹, R¹⁰, R¹³, n, X¹ and X² are as defined for formula I above; and

R¹² is selected from the group consisting of alkyl, aryl, heteroaryl, and heterocyclyl.

[0131] In certain embodiments, the reaction conditions to produce VI or VIA are hydrogenation reaction conditions. Such conditions typically comprise hydrogen. Such conditions also typically comprise a catalyst, such as a palladium catalyst (e.g. Pd/C, also known as palladium(0) on carbon). Alternatively, Pd(OH)₂/C or Raney nickel may be used.


[0132] In certain embodiments, the reaction conditions comprise a solvent selected from dichloromethane, ethyl acetate, or methanol. In particular embodiments, the reaction conditions comprise dichloromethane. In particular embodiments, the reaction conditions comprise ethyl acetate.

[0133] In some embodiments, the reaction is conducted in a hydrogen atmosphere and under pressure, e.g., at about 20 to about 300 psi, or at about 60 psi. In some embodiments, the reaction conditions comprise a base, such as sodium carbonate or sodium bicarbonate. In some embodiments, the hydrogenation reaction conditions comprise from about 0.5 to about 1 molar equivalents of sodium carbonate.

[0134] In certain embodiments, the reaction conditions comprise hydrogen, sodium carbonate, ethyl acetate, Pd/C, and a condition under pressure.

[0135] In certain embodiments, the reaction conditions comprise hydrogen, sodium carbonate, ethyl acetate, Pd/C, and a condition under pressure at about 60 psi.


[0136] In certain embodiments, the present invention is directed to a method of making a compound of formula VI or a stereoisomer or mixture of stereoisomers thereof:




VI

comprising the steps of:

1. a) contacting a compound of formula II with a compound of formula III




II



III

under reaction conditions sufficient to provide a compound of formula I:



I

2. b) contacting a compound of formula I with one of the following:

1. (i) a compound of formula



followed by a compound of formula




2. (ii) a compound of formula $\text{R}^{12}-\text{X}^3$ followed by a compound of formula




or


3. (iii) a compound of formula V:



under conditions sufficient to produce a compound of formula IV:



3. c) optionally converting a compound of formula VII:



to a compound of formula IV; and

4. d) converting a compound of formula IV under conditions sufficient to produce a compound of formula VI; wherein

X^3


is halo;

R^{12}

is selected from the group consisting of alkyl, aryl, heteroaryl, and heterocyclyl, or when two R^{12} are present, two R^{12} together with the carbon atom to which they are attached form a 4-8 membered heterocyclyl; and



Z , R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^8 , R^9 , R^{10} , R^{11} , R^{13} , n , X^1 and X^2 are as defined for formula I above.

[0137] In certain embodiments, the present invention is directed to a method of making a compound of formula VIA or a stereoisomer or mixture of stereoisomers thereof:




comprising the steps of:


1. a) contacting a compound of formula IIA with a compound of formula III




under reaction conditions to provide a compound of formula IA:




2. b) contacting a compound of formula IA with a compound of formula V



under reaction conditions sufficient to produce a compound of formula IVA:




3. c) optionally converting a compound of formula VIIA



to a compound of formula IVA; and


4. d) converting a compound of formula IVA under conditions sufficient to produce a compound of formula VIA;
wherein R², R³, R⁴, R⁵, R⁶, R⁸, R⁹, R¹⁰, R¹¹, R¹³, n, X¹ and X² are as defined for formula I above; and
R¹² is selected from the group consisting of alkyl, aryl, heteroaryl, and heterocyclyl.

[0138] In certain embodiments, the present invention is directed to a method of making a compound of formula VIC or a stereoisomer or mixture of stereoisomers thereof:




comprising the steps of:


1. a) contacting a compound of formula IIC with a compound of formula IIIA




under reaction conditions sufficient to provide a compound of formula IC:




2. b) contacting a compound of formula IC with a compound of formula VA



under reaction conditions sufficient to produce a compound of formula IVC:



3. c) optionally converting a compound of formula VIIC



to a compound of formula IVC; and

4. d) converting a compound of formula IVC under conditions sufficient to produce a compound of formula VIC;
wherein

R^2

is selected from the group consisting of hydrogen and alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl, and heteroaryl; and

R^4

is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halo, hydroxy, cyano, - $S(O)_n-N(R^8)-R^8$, - $NR^8C(O)NR^8R^8$, and - X^1R^8 ;


where X^1 is oxygen, - $S(O)_n$ -, or - NR^9 -;

n is 0, 1, or 2;

each R^8 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclyl and substituted heterocyclyl provided that when X^1 is - SO - or - SO_2 -, then R^8 is not hydrogen; and


R^9 is selected from the group consisting of hydrogen, alkyl, and aryl.

[0139] In certain embodiments, the present invention is directed to a method of making a compound of formula VID or a stereoisomer or mixture of stereoisomers thereof:




comprising the steps of:


1. a) contacting a compound of formula IID with a compound of formula IIIA




under reaction conditions to provide a compound of formula ID:




2. b) contacting a compound of formula ID with a compound of formula VA



under reaction conditions sufficient to produce a compound of formula IVD:



3. c) optionally converting a compound of formula VIID



to a compound of formula IVD; and

4. d) converting a compound of formula IVD under conditions sufficient to produce a compound of formula VID;
wherein

R^2

is selected from the group consisting of hydrogen and alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl, and heteroaryl; and

R^3

is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halo, hydroxy, cyano, - $S(O)_n-N(R^8)-R^8$, $-NR^8C(O)NR^8R^8$, and $-X^1R^8$;

where X^1 is oxygen, $-S(O)_n$, or $-NR^9$;

n is 0, 1, or 2;

each R^8 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclyl and substituted heterocyclyl provided that when X^1 is $-SO-$ or $-SO_2-$, then R^8 is not hydrogen; and

R^9 is selected from the group consisting of hydrogen, alkyl, and aryl.

[0140] In certain embodiments of the above methods, R^2 is hydrogen.

[0141] In certain embodiments of the above methods, R^2 is alkyl.

[0142] In certain embodiments of the above methods, R^3 is phenoxy.

[0143] In certain embodiments of the above methods, R^3 is 4-methoxyphenoxy.

[0144] In certain embodiments of the above methods, R^3 is 3,5-difluorophenoxy.

[0145] In certain embodiments of the above methods, R^4 is phenoxy.

[0146] In certain embodiments of the above methods, R^4 is 4-methoxyphenoxy.

[0147] In certain embodiments of the above methods, R^4 is 3,5-difluorophenoxy.

[0148] In certain embodiments of the above methods, R^2 is hydrogen and R^3 is phenoxy.

[0149] In certain embodiments of the above methods, R^2 is hydrogen and R^3 is 4-methoxyphenoxy.


[0150] In certain embodiments of the above methods, R^2 is hydrogen and R^3 is 3,5-difluorophenoxy.

[0151] In certain embodiments of the above methods, R² is hydrogen and R⁴ is phenoxy.

[0152] In certain embodiments of the above methods, R² is hydrogen and R⁴ is 4-methoxyphenoxy.


[0153] In certain embodiments of the above methods, R² is hydrogen and R⁴ is 3,5-difluorophenoxy.

[0154] In certain embodiments of the above methods described herein, the compound of formula VI is represented by formula VIB:




where R^2 , R^3 and R^4 are as defined for formula I above.

[0155] In certain embodiments of the above methods, the compound of formula II is represented by formula IIB:




wherein R², R³ and R⁴ are as defined for formula I above.


[0156] In certain embodiments of the above methods, the compound of formula III is represented by formula IIIA:



[0157] In certain embodiments of the above methods, the compound of formula III is represented by:




[0158] In certain embodiments of the above methods, the compound of formula I is represented by formula IB:




where R^2 , R^3 , R^4 and R^{11} are as defined for formula I above.


[0159] In certain embodiments of the above methods, the compound of formula V is represented by formula VA:



[0160] In certain embodiments of the above methods, the compound of formula V is represented by:




[0161] In certain embodiments of the above methods, the compound of formula VII is represented by formula VIIB:




where R^2 , R^3 , and R^4 are as defined for formula I above, and R^{12} is selected from the group consisting of alkyl, aryl, heteroaryl, and heterocyclyl.

[0162] In certain embodiments of the above methods, the compound of formula IV is represented by formula IVB:




where R^2 , R^3 , and R^4 are as defined for formula I above, and R^{12} is selected from the group consisting of alkyl, aryl, heteroaryl, and heterocyclyl.

[0163] In an alternative embodiment, the present invention is directed to a method of making compounds represented by formula X or a stereoisomer or mixture of stereoisomers thereof:




comprising the steps of:

1. a) contacting a compound of formula II with a compound of formula III



under reaction conditions sufficient to provide a compound of formula I:



2. b) contacting a compound of formula I with one of the following:

(iv) a compound of formula



followed by a compound of formula




(v) a compound of formula $R^{12}\text{-X}^3$ followed by a compound of formula




or


(vi) a compound of formula V:



under conditions sufficient to produce a compound of formula IV:




3. c) optionally converting a compound of formula VII:




to a compound of formula IV;

4. d) converting a compound of formula IV; under conditions sufficient to produce a compound of formula VI; and



5. e) contacting a compound of formula VI with a compound of formula



under reaction conditions sufficient to provide a compound of formula X: wherein

Z, R¹, R², R³, R⁴, R⁵, R⁶, R⁸, R⁹, R¹⁰, R¹¹, R¹³, n, X¹ and X²

are as defined for formula I above;

X³

is halo;

R¹²

is selected from the group consisting of alkyl, aryl, heteroaryl, and heterocyclyl, or when two R¹² are present, two R¹² together with the carbon atom to which they are attached form a 4-8 membered heterocyclyl;

p

is 0 when R^a is -COOH; p is 1 when R^a is -WR¹⁸;

W

is selected from the group consisting of oxygen, -S(O)_n- and -NR¹⁹- where n is 0, 1, or 2, R¹⁹ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl and substituted heterocyclyl and R¹⁸ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl and substituted heterocyclyl, or when W is -NR¹⁹- then R¹⁸ and R¹⁹, together with the nitrogen atom to which they are bound, can be joined to form a heterocyclyl or a substituted heterocyclyl group;

R

is selected from the group consisting of hydrogen, deuterium and methyl;

R'


is selected from the group consisting of hydrogen, deuterium, alkyl and substituted alkyl; alternatively, R and R' and the carbon pendent thereto can be joined to form cycloalkyl, substituted cycloalkyl, heterocyclyl or substituted heterocyclyl group; and

R''

is selected from the group consisting of hydrogen and alkyl or R'' together with R' and the nitrogen pendent thereto can be joined to form a heterocyclyl or substituted heterocyclyl group;


and pharmaceutically acceptable salts, stereoisomers, mixture of stereoisomers, and esters thereof.

[0164] In another embodiment, the present disclosure is directed to a method of making methyl 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate (3e):




comprising the steps of:


1. a) contacting a compound of formula 3a with a compound of formula IIIA




under reaction conditions sufficient to produce a compound of formula 3b:




2. b) contacting a compound of formula 3b with a compound of formula VA



under reaction conditions sufficient to produce a compound of formula 3c:




3. c) optionally converting a compound of formula 3d:




under reaction conditions sufficient to produce a compound of formula 3c; and

4. d) converting a compound of formula 3c under reaction conditions sufficient to produce a compound of formula 3e.

[0165] In another embodiment, the present disclosure is directed to a method of making 2-(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxamido)acetic acid (3f)




comprising contacting a compound of formula 3e with glycine or sodium glycinate



under reaction conditions sufficient to produce a compound of formula 3f.

[0166] Compounds of formula II:



for use in the methods disclosed herein can be prepared according to published procedures (see, for example, U.S. Patent No. 7,323,475).

[0167] In certain embodiments of the methods disclosed herein above, each of R^3 , R^4 , R^5 , R^6 , R^8 , R^9 , and R^{10} are as defined below:

R^3 and R^4 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, hydroxy, cyano, $-S(O)_n-N(R^8)-R^8$, $-NR^8C(O)NR^8R^8$, and $-X^1R^8$; where

X^1 is oxygen, $-S(O)_n$, or $-NR^9$;

n is 0, 1, or 2;

each R^8 is independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, heteroaryl, and heterocyclyl provided that when X^1 is $-SO-$ or $-SO_2-$, then R^8 is not hydrogen; and

R^9 is selected from the group consisting of hydrogen, alkyl, and aryl;

or R^3 and R^4 together with the carbon atoms pendent thereto, form a cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R^5 and R^6 are independently selected from the group consisting of hydrogen, halo, alkyl, alkoxy, aryl, heteroaryl, and $-X^2R^{10}$; where

X^2 is oxygen, $-S(O)_n$, or $-NR^{13}$;

n is 0, 1, or 2;

R^{10} is selected from the group consisting of alkyl, aryl, heteroaryl, and heterocyclyl; and

R^{13} is selected from the group consisting of hydrogen, alkyl, and aryl;

or when X^2 is $-NR^{13}$, then R^{10} and R^{13} , together with the nitrogen atom to which they are bound, can be joined to form a heterocyclyl group;

wherein each alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, and heterocyclyl described above can be optionally substituted with from 1 to 3 R^{100} ,

wherein each R^{100} is independently selected from the group consisting of alkoxy, acyl, acylamino, acyloxy, amino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, aryloxy, aryloxyaryl, cyano, halogen, hydroxyl, nitro, oxo, thio, carboxyl, carboxyl ester, cycloalkyl, thio, alkylthio, arylthio, cycloalkylthio, heteroarylthio, heterocyclheterocyclthio, sulfonyl, heteroaryl, heterocyclheterocyclyl, cycloalkoxy, heteroaryloxy, heterocyclloxy, oxycarbonylamino, oxythiocarbonylamino, $-OS(O)_2$ -alkyl, $-OS(O)_2$ -aryl, $-OS(O)_2$ -heteroaryl, $-OS(O)_2$ -heterocyclyl, $-OSO_2-NR^{40}R^{40}$, $-NR^{40}S(O)_2-NR^{40}$ -alkyl, $-NR^{40}S(O)_2-NR^{40}$ -aryl, $-NR^{40}S(O)_2-NR^{40}$ -heteroaryl, and $-NR^{40}S(O)_2-NR^{40}$ -heterocyclyl, where each R^{40} is independently selected from hydrogen and alkyl.

[0168] In certain embodiments of the above methods, R^1 is hydrogen.

[0169] In certain embodiments of the above methods, R^2 is hydrogen or alkyl.

[0170] In certain embodiments of the above methods,

R^3 and R^4

are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halo, hydroxy, cyano, $-S(O)_n-N(R^8)-R^8$, $-NR^8C(O)NR^8R^8$, and $-X^1R^8$;

where X^1 is oxygen, $-S(O)_n$, or $-NR^9$;

n is 0, 1, or 2;

each R^8 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl,

cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclyl and substituted heterocyclyl provided that when X^1 is $-SO-$ or $-SO_2-$, then R^8 is not hydrogen; and

R^9 is selected from the group consisting of hydrogen, alkyl, and aryl;

or R^3 and R^4

together with the carbon atoms pendent thereto, form a cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl.

[0171] In certain embodiments of the above methods,

R^3 and R^4

are independently selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, hydroxy, $-S(O)_n-N(R^8)-R^8$, $-NR^8C(O)NR^8R^8$, and $-X^1R^8$; where

X^1 is oxygen, $-S(O)_n-$, or $-NR^9-$;

n is 0, 1, or 2;

R^8 is aryl or substituted aryl; and

R^9 is hydrogen, alkyl or aryl;

or R^3 and R^4

together with the carbon atoms pendent thereto, form a cycloalkyl, heterocyclyl, aryl, or heteroaryl.

[0172] In certain embodiments of the above methods,

R^3 and R^4

are independently selected from the group consisting of hydrogen and $-X^1R^8$; where X^1 is oxygen, and R^8 is aryl or substituted aryl.

[0173] In certain embodiments of the above methods,

R^5 and R^6

are independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl and $-X^2R^{10}$;

where X^2 is oxygen, $-S(O)_n-$, or $-NR^{13}-$;

n is 0, 1, or 2;

R^{10} is aryl or substituted aryl; and

R^{13} is selected from the group consisting of hydrogen, alkyl, and aryl.

[0174] In certain embodiments of the above methods,

R^5 and R^6

are independently selected from the group consisting of hydrogen and $-X^2R^{10}$; where X^2 is oxygen, and R^{10} is aryl or substituted aryl.

[0175] In certain embodiments of the above methods, R^5 and R^6 are hydrogen.

[0176] In certain embodiments of the above methods,

R²

is hydrogen or alkyl;

R³ and R⁴

are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halo, hydroxy, cyano, -S(O)_n-N(R⁸)-R⁸, -NR⁸C(O)NR⁸R⁸, and -X¹R⁸;

where X¹ is oxygen, -S(O)_n, or -NR⁹-;

n is 0, 1, or 2;

each R⁸ is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclyl and substituted heterocyclyl provided that when X¹ is -SO- or -SO₂-, then R⁸ is not hydrogen; and

R⁹ is selected from the group consisting of hydrogen, alkyl, and aryl;

or R³ and R⁴

together with the carbon atoms pendent thereto, form a cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl; and

R⁵ and R⁶

are independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl and -X²R¹⁰;

where X² is oxygen, -S(O)_n, or -NR¹³-;

n is 0, 1, or 2;

R¹⁰ is aryl or substituted aryl; and

R¹³ is selected from the group consisting of hydrogen, alkyl, and aryl.

[0177] In certain embodiments of the above methods,

R²

is hydrogen or alkyl;

R³ and R⁴

are independently selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, hydroxy, -S(O)_n-N(R⁸)-R⁸, -NR⁸C(O)NR⁸R⁸, and -X¹R⁸; where

X¹ is oxygen, -S(O)_n, or -NR⁹-;

n is 0, 1, or 2;

R⁸ is aryl or substituted aryl; and

R⁹ is hydrogen, alkyl or aryl;

or R³ and R⁴

together with the carbon atoms pendent thereto, form a cycloalkyl, heterocyclyl, aryl, or heteroaryl; and

R⁵ and R⁶

are independently selected from the group consisting of hydrogen and -X²R¹⁰; where X² is oxygen, and R¹⁰ is aryl or substituted aryl.

[0178] In certain embodiments of the above methods,

R²

is hydrogen or alkyl;

R³ and R⁴ are

independently selected from the group consisting of hydrogen and -X¹R⁸; where X¹ is oxygen, and R⁸ is aryl or substituted aryl; and

R⁵ and R⁶

are hydrogen.

[0179] In certain embodiments of the above methods, R¹¹ is C₁ to C₄ alkyl.


[0180] In certain embodiments of the above methods, R¹¹ is methyl.

[0181] In certain embodiments of the above methods, R¹² is C₁ to C₄ alkyl.


[0182] In certain embodiments of the above methods, R¹² is methyl.

[0183] In certain embodiments of the methods disclosed hereinabove, the methods further comprise the step of forming a corresponding salt of the compound. Such methods are well known in the art.

[0184] Other modifications to arrive at compounds of this invention are well within the skill of the art. For example, modification of the C-4 hydroxy group may be done by conventional means to corresponding ethers, acyloxy etc. to provide compounds of the invention. Specifically, esters can be prepared under standard coupling conditions by reacting a carboxylic acid containing compound with a compound comprising an alcohol in a suitable solvent, optionally at elevated temperatures. Accordingly, esters of the compounds disclosed herein can be formed at any carboxylic acid or hydroxyl functional group. Typical ester forming reactions to provide the compounds of the invention are shown below, where R² is as defined herein.




[0185] The N-oxide derivatives of the above described compounds can also be prepared using methods known within the skill of the art. Accordingly, compounds of the invention include N-oxide derivatives of the formula:



Compounds of the Invention

[0186] In another aspect, the invention is directed to a compound of formula VIII:



wherein:

Z

is O, NR¹, or S;

R¹

is selected from the group consisting of hydrogen and alkyl;

R²

is selected from the group consisting of hydrogen and alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl, and heteroaryl;

R³ and R⁴

are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halo, hydroxy, cyano, -S(O)_n-

$N(R^8)-R^8$, $-NR^8C(O)NR^8R^8$, and $-X^1R^8$;

where X^1 is oxygen, $-S(O)_n$, or $-NR^9$;

n is 0, 1, or 2;

each R^8 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclyl and substituted heterocyclyl provided that when X^1 is $-SO$ or $-SO_2$, then R^8 is not hydrogen; and

R^9 is selected from the group consisting of hydrogen, alkyl, and aryl; or R^3 and R^4 together with the carbon atoms pendent thereto, form a cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

R^5 and R^6

are independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl and $-X^2R^{10}$;

where X^2 is oxygen, $-S(O)_n$, or $-NR^{13}$;

n is 0, 1, or 2;

R^{10} is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl and substituted heterocyclyl; and

R^{13} is selected from the group consisting of hydrogen, alkyl, and aryl; or when X^2 is $-NR^{13}$, then R^{10} and R^{13} , together with the nitrogen atom to which they are bound, can be joined to form a heterocyclyl or substituted heterocyclyl group; and

R^7

is either $-N(R^{11})(R^{11})$ or $-OC(O)R^{12}$;

each R^{11}

is independently selected from alkyl, benzyl and aryl, or two R^{11} together with the nitrogen atom to which they are attached form a 4-8 membered heterocyclyl or a heteroaryl; and


R^{12}

is selected from the group consisting of alkyl, aryl, heteroaryl, and heterocyclyl;

or a salt, ester, stereoisomer, or mixture of stereoisomers thereof;

provided that the compound is not 1-dimethylaminomethyl-4-hydroxy-7-phenylsulfanyl-isoquinoline-3-carboxylic acid butyl ester.

[0187] In certain embodiments, the present invention is directed to a compound of formula VIII A:



wherein:

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, n, X^1$ and X^2 are as defined for formula VIII above;

or a salt, ester, stereoisomer, or mixture of stereoisomers thereof;

provided that the compound is not 1-dimethylaminomethyl-4-hydroxy-7-phenylsulfanyl-isoquinoline-3-carboxylic acid butyl ester.

[0188] In certain embodiments of the above compounds, R^2 is hydrogen, alkyl, or substituted alkyl.

[0189] In certain embodiments, R^2 is alkyl.

[0190] In certain embodiments, R^3 and R^4 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, hydroxy, $-S(O)_n-N(R^8)-R^8$, $-NR^8C(O)NR^8R^8$, and $-X^1R^8$; where

X^1 is oxygen, $-S(O)_n$, or $-NR^9$;

n is 0, 1, or 2;

R^8 is aryl or substituted aryl, and

R^9 is hydrogen, alkyl, or aryl;

or R^3 and R^4 together with the carbon atoms pendent thereto, form a cycloalkyl, heterocyclyl, aryl, or heteroaryl.

[0191] In certain embodiments, R⁵ and R⁶ are hydrogen.

[0192] In certain embodiments, R^2 is alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl, and heteroaryl; and R^5 and R^6 are hydrogen.

[0193] In certain embodiments, R⁷ is -OC(O)R¹². In certain embodiments, R⁷ is -N(R¹¹)(R¹¹). In certain embodiments, R⁷ is -N(R¹¹)(R¹¹); and R¹ is C₁ to C₄ alkyl. In certain embodiments, R⁷ is -OC(O)R¹²; and R¹² is C₁ to C₄ alkyl.

[0194] In certain embodiments, Z is O.

[0195] In certain embodiments of the compounds disclosed hereinabove, each of R³, R⁴, R⁵, R⁶, R⁸, and R¹⁰ are as defined below.

R³ and R⁴ are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, hydroxy, cyano, -S(O)_n-N(R⁸)-R⁸, -NR⁸C(O)NR⁸R⁸, and -X¹R⁸, where

X¹ is oxygen, -S(O)_n-, or -NR⁹-;

n is 0, 1, or 2;

each R⁸ is independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, heteroaryl, and heterocyclyl; and

R⁹ is selected from the group consisting of hydrogen, alkyl, and aryl;

or R³ and R⁴ together with the carbon atoms pendent thereto, form a cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R⁵ and R⁶ are independently selected from the group consisting of hydrogen, halo, alkyl, alkoxy, aryl, heteroaryl, and -X²R¹⁰; where

X^2 is oxygen, $-S(O)_n-$, or $-NR^{13}-$;

n is 0, 1, or 2;

R¹⁰ is selected from the group consisting of alkyl, aryl, heteroaryl, and heterocyclyl; and

R¹³ is selected from the group consisting of hydrogen, alkyl, and aryl;


or when X^2 is $-NR^{13}$ -, then R^{10} and R^{13} , together with the nitrogen atom to which they are bound, can be joined to form a heterocyclyl group;

wherein each alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, and heterocyclyl described above can be optionally substituted with from 1 to 3 R¹⁰⁰.

wherein each R¹⁰⁰ is independently selected from the group consisting of alkoxy, acyl, acylamino, acyloxy, amino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, aryloxy, aryloxyaryl, cyano, halogen, hydroxyl, nitro, oxo, thio, carboxyl, carboxyl ester, cycloalkyl, thio, alkylthio, arylthio, cycloalkylthio, heteroarylthio, heterocyclicheterocyclylthio, sulfonyl, heteroaryl, heterocyclicheterocyclyl, cycloalkoxy, heteroaryloxy, heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O)₂-alkyl, -OS(O)₂-aryl, -OS(O)₂-heteroaryl, -OS(O)₂-heterocyclyl, -OSO₂-NR⁴⁰R⁴⁰, -NR⁴⁰S(O)₂-NR⁴⁰-alkyl, -NR⁴⁰S(O)₂-NR⁴⁰-aryl, -NR⁴⁰S(O)₂-NR⁴⁰-heteroaryl, and -NR⁴⁰S(O)₂-NR⁴⁰-heterocyclyl, where each R⁴⁰ is independently selected from hydrogen and alkyl;


provided that the compound is not 1-dimethylaminomethyl-4-hydroxy-7-phenylsulfanyl-isoquinoline-3-carboxylic acid butyl ester.

[0196] In another aspect, the invention is directed to 4-hydroxy-7-phenoxyisoquinoline-3-carboxylic acid methyl ester (3a):



Isoquinoline Synthesis

[0197] The compounds and methods of the invention can be used for the synthesis of various isoquinoline compounds. Such compounds are known to be useful for inhibiting HIF hydroxylase activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF), and can be used to treat and prevent HIF-associated conditions and disorders (see, *e.g.*, U.S. Patent No. 7,323,475). Exemplary substituted isoquinoline compounds which can be prepared using the methods disclosed herein include those represented by formula X:



wherein R^3 , R^4 , R^5 and R^6 are as defined for formula I above and:

p is 0 when R^a is $-COOH$; p is 1 when R^a is $-WR^{18}$;

W is selected from the group consisting of oxygen, $-S(O)_n-$ and $-NR^{19}-$ where n is 0, 1, or 2, R^{19} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl and substituted heterocyclyl and R^{18} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl and substituted heterocyclyl, or when W is $-NR^{19}-$ then R^{18} and R^{19} , together with the nitrogen atom to which they are bound, can be joined to form a heterocyclyl or a substituted heterocyclyl group;

R is selected from the group consisting of hydrogen, deuterium and methyl;


R' is selected from the group consisting of hydrogen, deuterium, alkyl and substituted alkyl; alternatively, R and R' and the carbon pendent thereto can be joined to form cycloalkyl, substituted cycloalkyl, heterocyclyl or substituted heterocyclyl group;

R'' is selected from the group consisting of hydrogen and alkyl or R'' together with R' and the nitrogen pendent thereto can be joined to form a heterocyclyl or substituted heterocyclyl group;

and pharmaceutically acceptable salts, stereoisomers, mixture of stereoisomers, and esters thereof.

[0198] Exemplary methods for the preparation of compounds described herein are shown in the Schemes below, where Z , X^3 , R^2 , R^3 , R^4 , R^5 , R^6 , R^{11} , R^{12} , p , R^a , R , R' and R'' are as defined for formula I and formula X above, and PG is a standard amine protecting group.

Scheme A




[0199] Compounds **A-200** for use in the reactions depicted in **Scheme A**, can be prepared by contacting compounds **A-100** with a suitable Lewis acid such as trimethyl borate, in the presence of a halogenating agent, such as dichlorotriphenylphosphorane and thionyl chloride to generate the acyl halide, which upon contact with an alcohol of the formula R^2-OH , such as methanol, yields the corresponding halogenated ester **A-200**. Upon reaction completion, **A-200** can be recovered by conventional techniques such as neutralization, extraction, precipitation, chromatography, filtration, and the like; or, alternatively, used in the next step without purification and/or isolation.

[0200] Compounds **A-200** can be modified to **A-300** (formula II) by contacting **A-200** with about a stoichiometric amount of a suitable alpha-amino acid of formula **A-10** (wherein PG refers to a suitable protecting group such as mesyl, tosyl, etc.) and a catalytic amount of sodium iodide. The reaction is conducted under conventional coupling conditions well known in the art. A suitable base is then added, such as sodium methoxide, sodium ethoxide or another suitable base in methanol, DMF or another suitable solvent. The reaction is continued until it is substantially complete which typically occurs within about 1 to 72 h. Upon reaction completion, the compounds **A-300** can be recovered by conventional techniques such as neutralization, extraction, precipitation, chromatography, filtration and the like.

[0201] Compounds **A-300** can be modified to **B-100** (formula I) by the methods of the present invention as shown in **Scheme B**.


Scheme B



[0202] For example, contacting **A-300** with about a stoichiometric amount or a slight excess thereof of a compound of formula **A-20** (formula III) in the presence of an acid, such as acetic acid, provides compounds **B-100**. The reaction is continued until it is substantially complete which typically occurs within about 1 to 72 h. Upon reaction completion, the compounds **B-100** may be recovered by conventional techniques such as neutralization, extraction, precipitation, chromatography, filtration and the like, or used in the next step without isolation and/or purification.

[0203] Compounds **B-100** (formula I) can be modified to compounds **C-100** (formula VII) and **C-200** (formula IV) by the methods of the present invention as shown in **Scheme C**.

Scheme C



[0204] For example, contacting **B-100** with an excess (e.g. 2 - 3 equivalents) of compound **A-30** (formula V) in the presence of an acid, such as acetic acid, provides compounds **C-100** and **C-200**. Alternatively, contacting **B-100** with an acyl halide of formula $R^{12}-C(O)X^3$ or an alkyl halide of formula $R^{12}-X^3$, followed by an acid of formula $R^{12}-C(O)OH$, such as acetic acid, provides compounds **C-100** and **C-200**. The reaction is typically conducted at temperatures of about 100 °C, and is continued until it is substantially complete which typically occurs within about 1 to 72 h. Compounds **C-200** can be provided by the methods of the present invention, such as reaction of the mixture of compounds **C-100** and **C-200** with an amine, such as morpholine in a suitable polar solvent, such as DMF. The reaction is typically performed at temperatures below room temperature (i.e. 0 to 10 °C). Upon reaction completion, the compounds **C-200** can be recovered by conventional techniques such as neutralization, extraction, precipitation, chromatography, filtration and the like.


[0205] Compounds **C-200** (formula IV) can be modified to **C-300** (formula VI) under reaction conditions according to the present invention. In certain embodiments, the reaction conditions are hydrogenation reaction conditions. Such conditions typically comprise a catalyst, such as a palladium catalyst (e.g. palladium(0) on carbon), under a hydrogen atmosphere. In some

embodiments, the hydrogenation reaction is conducted under pressure. In some embodiments, the hydrogenation reaction conditions comprise a base, such as sodium carbonate. In some embodiments, the hydrogenation reaction conditions comprise from about 0.5 to about 1 molar equivalents of sodium carbonate.

[0206] Compounds **C-400** (formula X) can be synthesized by contacting compounds **C-300** (formula VI) with at least a stoichiometric amount or an excess of a suitable amino acid or derivative thereof **A-40** (particularly, but not limited to, glycine or its corresponding salts). The reaction is conducted under conventional coupling conditions well known in the art. In one embodiment, the reaction is conducted in the presence of sodium methoxide, sodium ethoxide or another suitable base in methanol, DMF or another suitable solvent under elevated reaction temperatures and particularly at reflux. The reaction is continued until it is substantially complete which typically occurs within about 1 to 72 h. Alternatively, the reaction can be performed at elevated temperatures in a microwave oven. Upon reaction completion, the compounds **C-400** can be recovered by conventional techniques such as neutralization, extraction, precipitation, chromatography, filtration and the like.

[0207] Specific methods for the preparation of such substituted isoquinoline compounds are shown in **Scheme D** below, where R^2 , R^3 , R^4 , R^5 , R^{11} , R^{12} , p , R^a , R' and R'' are as defined herein, and PG is a standard amine protecting group.

Scheme D



[0208] Compounds **D-100** for use in the reactions depicted in **Scheme D**, can be prepared by contacting compounds **A-100** with a suitable Lewis acid such as trimethyl borate, in the presence of dichlorotriphenylphosphorane and thionyl chloride to generate the acyl chloride, which upon contact with an alcohol, such as methanol, yields the corresponding ester **D-100**. Upon reaction completion, **D-100** can be recovered by conventional techniques such as neutralization, extraction, precipitation, chromatography, filtration, and the like; or, alternatively, used in the next step without purification and/or isolation.

[0209] Compounds **D-100** can be modified to **D-200** (formula IIa) by contacting **D-100** with about a stoichiometric amount of a suitable alpha-amino acid of formula **D-10** (wherein PG refers to a suitable protecting group such as mesyl, tosyl, etc.) and a catalytic amount of sodium iodide. The reaction is conducted under conventional coupling conditions well known in the art. A suitable base is then added, such as sodium methoxide, sodium ethoxide or another suitable base in methanol, DMF or another suitable solvent. The reaction is continued until it is substantially complete which typically occurs within about 1 to 72 h. Upon reaction completion, the compounds **D-200** can be recovered by conventional techniques such as neutralization, extraction, precipitation, chromatography, filtration and the like.

[0210] Compounds **D-200** can be modified to **D-300** (formula Ia) by the methods of the present invention. For example, contacting **D-200** with about a stoichiometric amount or a slight excess thereof of a compound of formula **A-20** in the presence of an acid, such as acetic acid, provides compounds **D-300**. The reaction is continued until it is substantially complete which typically occurs within about 1 to 72 h. Upon reaction completion, the compounds **D-300** can be recovered by conventional techniques

such as neutralization, extraction, precipitation, chromatography, filtration and the like.

[0211] Compounds **D-300** can be modified to compounds **D-400** (formula VIIA) and **D-500** (formula IVA) by the methods of the present invention. For example, contacting **D-300** with an excess (e.g. 2 - 3 equivalents) of compound **A-30** in the presence of an acid, such as acetic acid, provides compounds **D-400** and **D-500**. The reaction is typically conducted at temperatures of about 100 °C, and is continued until it is substantially complete which typically occurs within about 1 to 72 h. Compounds **D-500** can be provided by the methods of the present invention, such as reaction of the mixture of compounds **D-400** and **D-500** with an amine, such as morpholine in a suitable polar solvent, such as DMF. The reaction is typically performed at temperatures below room temperature (e.g., 0 to 10 °C). Upon reaction completion, the compounds **D-500** can be recovered by conventional techniques such as neutralization, extraction, precipitation, chromatography, filtration and the like.


[0212] Compounds **D-500** can be modified to **D-600** (formula VIA) under reaction conditions according to the present invention. In certain embodiments, the reaction conditions are hydrogenation reaction conditions. Such conditions typically comprise a catalyst, such as a palladium catalyst (e.g. palladium(0) on carbon), under a hydrogen atmosphere. In some embodiments, the hydrogenation reaction is conducted under pressure. In some embodiments, the hydrogenation reaction conditions comprise a base, such as sodium carbonate. In some embodiments, the hydrogenation reaction conditions comprise from about 0.5 to about 1 molar equivalents of sodium carbonate.

[0213] Compounds **C-400** (formula X) can be synthesized by contacting compounds **D-600** with at least a stoichiometric amount or an excess of a suitable amino acid or derivative thereof **A-40** (particularly, but not limited to, glycine or its corresponding salts). The reaction is conducted under conventional coupling conditions well known in the art. In one embodiment, the reaction is conducted in the presence of sodium methoxide, sodium ethoxide or another suitable base in methanol, DMF or another suitable solvent under elevated reaction temperatures and particularly at reflux. The reaction is continued until it is substantially complete which typically occurs within about 1 to 72 h. Alternatively, the reaction can be performed at elevated temperatures in a microwave oven. Upon reaction completion, the compounds **C-400** can be recovered by conventional techniques such as neutralization, extraction, precipitation, chromatography, filtration and the like.

[0214] The compounds **A-100**, **A-10**, **A-20**, **A-30**, **A-40**, and **D-10** for use in the reactions depicted in the above Schemes are either available from commercial sources or can be prepared according to known literature procedures. Other modifications to the compounds provided by this invention are well within the skill of the art. For example, modification of the C-4 hydroxy group may be done by conventional means to corresponding ethers, acyloxy, and the like. In addition, compounds **A-40** can be used as provided in U.S. Patent No. 7,323,475.

[0215] In the art, isoquinoline compounds have been prepared according to methods which are not desirable for large scale production (Scheme E, where R²⁰ is a general abbreviation that represents a substituent group as described herein (i.e., alkyl, alkoxy, aryl, aryloxy, etc)). Exemplary substituent groups include alkyl, alkoxy, heteroalkyl, aryl, aryloxy, etc., each as defined herein. For example, isoquinoline compounds prepared according to U.S. Patent No. 7,323,475 involve the undesirable chromatographic separation of regioisomers **E-200** and **E-300**. It is contemplated that such a process would be inefficient on a large scale. In addition, the conversion of **E-400** to the corresponding bromide **E-500** in order to furnish the alkyl substitution on the isoquinoline ring of compounds **E-600** requires the use of phosphorus oxybromide which is both toxic and potentially explosive. Advantageously, in contrast to methods previously disclosed, the methods of the present invention do not require the use of such hazardous reagents for the synthesis of isoquinoline compounds.

Scheme E



[0216] The synthesis of 1-dimethylaminomethyl-4-hydroxy-7-phenylsulfanyl-isoquinoline-3-carboxylic acid butyl ester has been reported in U.S. Patent No. 7,323,475, using a mixture of 4-hydroxy-7-phenylsulfanyl-isoquinoline-3-carboxylic acid butyl ester, N,N-dimethylmethyleammonium iodide, and potassium carbonate in anhydrous dichloromethane. However, only 16% of the

desired 1-dimethylaminomethyl-4-hydroxy-7-phenylsulfanyl-isoquinoline-3-carboxylic acid butyl ester was obtained. Advantageously, in contrast to methods previously disclosed, the methods of the present invention provide good yields for the synthesis of compounds described herein.

Examples

[0217] The invention is further understood by reference to the following examples, which are intended to be purely exemplary of the invention. The present invention is not limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of the invention only. Any methods that are functionally equivalent are within the scope of the invention. Various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications fall within the scope of the appended claims.

[0218] Unless otherwise stated all temperatures are in degrees Celsius (°C). Also, in these examples and elsewhere, abbreviations have the following meanings:

EtOH

= Ethanol

Et

= Ethyl

g

= Gram

h

= Hour

HPLC

= High-performance liquid chromatography

L

= Liter

MeOH

= Methanol

mg

= Milligram

min

= Minute

mL

= Milliliter

mM

= Millimolar

mmol

= Millimole

Ac

= Acetyl

NaOMe


= Sodium methoxide

EXAMPLE 1

Preparation of 2-(4-hydroxy-1-methyl-5-phenoxyisoquinoline-3-carboxamido)acetic acid

a) Preparation of methyl 1-((dimethylamino)methyl)-4-hydroxy-5-phenoxyisoquinoline-3-carboxylate (1b)


[0219]



[0220] A round bottom flask fitted with thermocouple and condenser can be charged with **1a** and acetic acid (about 7 molar equivalents $\pm$ 5%). The suspension of **1a** in acetic acid can be stirred vigorously with magnetic stirring (note: overhead stirring should be done for larger scale work). A slight excess of bis-dimethylaminomethane (about 1.25 molar equivalents) can then be slowly added to the mixture [Note: Reaction is slightly exothermic, 15-20 °C temperature rise can be observed]. After the addition is complete, the mixture can be heated to 55 ± 5 °C and maintained for at least 8 h. The reaction can then be evaluated by HPLC. If the amount of **1a** is greater than 0.5%, the reaction can be stirred for additional 2 hours at 55 ± 5 °C and reevaluated by HPLC.

b) Preparation of methyl 1-((acetoxymethyl)-4-hydroxy-5-phenoxyisoquinoline-3-carboxylate (1c**)**

[0221]




[0222] The solution of **1b** from Example 1a) can be cooled to below 25 °C, at which time acetic anhydride (about 3 molar equivalents) can be added slowly at a temperature below 50 °C [Note: Reaction is exothermic, 20-25 °C temperature rise can be observed. Rate of addition is important to control the exothermic reaction between acetic anhydride and dimethyl amine of **1b**. Excess heat generated will cause unsafe rapid evolution of gaseous dimethyl amine]. After the addition is complete, the mixture can be heated to 100 ± 5 °C for 20-24 hours. The reaction can then be evaluated by HPLC. If **1b** is in an amount greater than 2%, the reaction can be stirred for an additional 2 hours and then reevaluated by HPLC.

[0223] **1d** can be converted to **1c** by the following procedure. The solution of **1c** and **1d** from the above procedure can be cooled to less than 65 ± 5 °C with good mixing. If the reaction temperature goes below 30 °C, the reaction may solidify. Water can be slowly and steadily added (the first half can be added over 1 hour and the rest added over 30 minutes). The mixture can then be cooled and stirred at 20 ± 5 °C for at least 3 hours, at which time the mixture can be filtered and the wet cake washed with water (3X) and added to a round bottom flask fitted with a mechanical stirrer. Dichloromethane and water (3:1 by volume) can be added and the mixture stirred for 30 minutes. The dichloromethane can be separated (without including the interface or aqueous layer) and the solution evaluated by HPLC.

[0224] **1c** can be further purified according to the following procedure. The above solution can be added to a flask, fitted with mechanical stirrer, and cooled to 5 ± 5 °C. Morpholine can be added and the mixture stirred at 5 ± 5 °C for 30-60 minutes and evaluated by HPLC. If the amount of **1d** is greater than 2%, the reaction can be stirred for an additional hour. Once the reaction reached completion, **1c** can be precipitated from cold acetone/methanol solution, filtered, washed and dried under vacuum at 50 ± 5 °C.

c) Preparation of methyl 4-hydroxy-1-methyl-5-phenoxyisoquinoline-3-carboxylate (1e**)**


[0225]



[0226] A glass lined Parr pressure reactor vessel equipped with a 4-blade impeller can be charged with **1c**, Pd/C (about 0.4 to 0.5 molar equivalents), anhydrous Na₂CO₃ (about 0.5 molar equivalents), and ethyl acetate. The flask can then be vacuum-purged with nitrogen (3X) and vacuum-purged with hydrogen (3X). The flask can then be pressurized with hydrogen to set point 60 psi and stirred at 60 °C for 6-8 hrs until completion of reaction (**1c** <0.5%). The flask can then be cooled to 20-25 °C, the pressure released to ambient, the head space purged with nitrogen three times and filtered through glass microfiber filter paper. The filtrate can be concentrated and precipitated from cold methanol and dried under vacuum at 50 ± 5 °C.

d) Preparation of 2-(4-hydroxy-1-methyl-5-phenoxyisoquinoline-3-carboxamido)acetic acid (1f**)**

[0227]



[0228] 2-(4-Hydroxy-1-methyl-5-phenoxyisoquinoline-3-carboxamido)acetic acid can be prepared from **1e** according to the following procedure.


[0229] A pressure glass reaction flask which included top threads for a screw cap lid can be fitted with a magnetic stirrer, charged with **1e**, glycine (about 3 molar equivalents), methanol, and a sodium methoxide solution (with 1.2 molar equivalents NaOCH₃) and sealed. The reaction can then be heated to 110 °C for at least 6 h during which time the reaction forms a yellow suspension. The reaction can then be cooled to 20-25 °C and evaluated by HPLC. The reaction can be continued until less than 1% **1e** remains as determined by HPLC, filtered, washed with methanol, dried under vacuum, dissolved in water and extracted with ethyl acetate to remove impurities to below 0.1 %. The ethyl acetate can be removed and an acetic acid solution (with 3 molar equivalents acetic acid) can be added over one hour. The suspension can be stirred at room temperature for at least 3 hours, filtered, and the solid washed with water (3X), cold acetone (5-10 °C, 2X) and evaluated for impurities by HPLC. If acetone removable impurities are present, the flask can be charged with acetone and refluxed for at least 8 h, slowly cooled to 5-10 °C, stirred for at least 2-3 h, filtered, washed with cold acetone (5-10 °C, 3X) and dried under vacuum to obtain 2-(4-hydroxy-1-methyl-5-phenoxyisoquinoline-3-carboxamido)acetic acid.

EXAMPLE 2


Preparation of 2-(4-hydroxy-1-methyl-6-phenoxyisoquinoline-3-carboxamido)acetic acid

a) Preparation of methyl 1-((dimethylamino)methyl)-4-hydroxy-6-phenoxyisoquinoline-3-carboxylate (2b**)**

[0230]




[0231] A round bottom flask fitted with thermocouple and condenser can be charged with **2a** and acetic acid (about 7 molar equivalents ± 5%). The suspension of **2a** in acetic acid can be stirred vigorously with magnetic stirring (note: overhead stirring should be done for larger scale work). A slight excess of bis-dimethylaminomethane (about 1.25 molar equivalents) can then be slowly added to the mixture [Note: Reaction is slightly exothermic, 15-20 °C temperature rise can be observed]. After the addition is complete, the mixture can be heated to 55 ± 5 °C and maintained for at least 8 h. The reaction can then be evaluated by HPLC. If the amount of **2a** is greater than 0.5%, the reaction can be stirred for additional 2 hours at 55 ± 5 °C and reevaluated by HPLC.

b) Preparation of methyl 1-((acetoxymethyl)-4-hydroxy-6-phenoxyisoquinoline-3-carboxylate (2c)**[0232]**

[0233] The solution of **2b** from Example 2a) can be cooled to below 25 °C, at which time acetic anhydride (about 3 molar equivalents) can be added slowly at a temperature below 50 °C [Note: Reaction is exothermic, 20-25 °C temperature rise can be observed. Rate of addition is important to control the exothermic reaction between acetic anhydride and dimethyl amine or **2b**. Excess heat generated will cause unsafe rapid evolution of gaseous dimethyl amine]. After the addition is complete, the mixture can be heated to 100 ± 5 °C for 20-24 hours. The reaction can then be evaluated by HPLC. If **2b** is in an amount greater than 2%, the reaction can be stirred for an additional 2 hours and then reevaluated by HPLC.


[0234] **2d** can be converted to **2c** by the following procedure. The solution of **2c** and **2d** from the above procedure can be cooled to less than 65 ± 5 °C with good mixing. If the reaction temperature goes below 30 °C, the reaction may solidify. Water can be slowly and steadily added (the first half can be added over 1 hour and the rest added over 30 minutes). The mixture can then be cooled and stirred at 20±5°C for at least 3 hours, at which time the mixture can be filtered and the wet cake washed with water (3X) and added to a round bottom flask fitted with a mechanical stirrer. Dichloromethane and water (3:1 by volume) can be added and the mixture stirred for 30 minutes. The dichloromethane can be separated (without including the interface or aqueous layer) and the solution evaluated by HPLC.

[0235] **2c** can be further purified according to the following procedure. The above solution can be added to a flask, fitted with mechanical stirrer, and cooled to 5 ± 5 °C. Morpholine can be added and the mixture stirred at 5 ± 5 °C for 30-60 minutes and evaluated by HPLC. If the amount of **2d** is greater than 2%, the reaction can be stirred for an additional hour. Once the reaction reached completion, **2c** can be precipitated from cold acetone/methanol solution, filtered, washed and dried under vacuum at 50 ± 5 °C.

c) Preparation of methyl 4-hydroxy-1-methyl-6-phenoxyisoquinoline-3-carboxylate (2e)**[0236]**

[0237] A glass lined Parr pressure reactor vessel equipped with a 4-blade impeller can be charged with **2c**, Pd/C (about 0.4 to 0.5 molar equivalents), anhydrous Na₂CO₃ (about 0.5 molar equivalents), and ethyl acetate. The flask can then be vacuum-purged with nitrogen (3X) and vacuum-purged with hydrogen (3X). The flask can then be pressurized with hydrogen to set point 60 psi and stirred at 60 °C for 6-8 hrs until completion of reaction (2c <0.5%). The flask can then be cooled to 20-25 °C, the pressure released to ambient, the head space purged with nitrogen three times and filtered through glass microfiber filter paper. The filtrate can be concentrated and precipitated from cold methanol and dried under vacuum at 50 ± 5 °C.

d) Preparation of 2-(4-hydroxy-1-methyl-6-phenoxyisoquinoline-3-carboxamido)acetic acid (2f)**[0238]**



[0239] 2-(4-Hydroxy-1-methyl-6-phenoxyisoquinoline-3-carboxamido)acetic acid is prepared from **2e** according to the following procedure.


[0240] A pressure glass reaction flask which included top threads for a screw cap lid can be fitted with a magnetic stirrer, charged with **2e**, glycine (about 3 molar equivalents), methanol, and a sodium methoxide solution (with 1.2 molar equivalents NaOCH_3) and sealed. The reaction can then be heated to 110 °C for at least 6 h during which time the reaction forms a yellow suspension. The reaction can then be cooled to 20-25 °C and evaluated by HPLC. The reaction can be continued until less than 1% **2e** remains as determined by HPLC, filtered, washed with methanol, dried under vacuum, dissolved in water and extracted with ethyl acetate to remove impurities to below 0.1 %. The ethyl acetate can be removed and an acetic acid solution (with 3 molar equivalents acetic acid) can be added over one hour. The suspension can be stirred at room temperature for at least 3 hours, filtered, and the solid washed with water (3X), cold acetone (5-10 °C, 2X) and evaluated for impurities by HPLC. If acetone removable impurities are present, the flask can be charged with acetone and refluxed for at least 8 h, slowly cooled to 5-10 °C, stirred for at least 2-3 h, filtered, washed with cold acetone (5-10 °C, 3X) and dried under vacuum to obtain 2-(4-hydroxy-1-methyl-6-phenoxyisoquinoline-3-carboxamido)acetic acid.

EXAMPLE 3

Preparation of 2-(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxamido)acetic acid

a) Preparation of 5-phenoxyphthalide


[0241]



[0242] A reactor was charged with DMF (68 Kg), and stirring was initiated. The reactor was then charged with phenol (51 Kg), acetylacetone (8 Kg), 5-bromophthalide (85 Kg), copper bromide (9 Kg), and potassium carbonate (77 Kg). The mixture was heated above 85 °C and maintained until reaction completion and then cooled. Water was added. Solid was filtered and washed with water. Solid was dissolved in dichloromethane, and washed with aqueous HCl and then with water. Solvent was removed under pressure and methanol was added. The mixture was stirred and filtered. Solid was washed with methanol and dried in an oven giving 5-phenoxyphthalide (Yield: 72%, HPLC: 99.6%).

b) Preparation of 2-chloromethyl-4-phenoxybenzoic acid methyl ester

[0243]




[0244] A reactor was charged with toluene (24 Kg), and stirring was initiated. The reactor was then charged with 5-phenoxyphthalide (56 Kg), thionyl chloride (41 Kg), trimethyl borate (1 Kg), dichlorotriphenylphosphorane (2.5 Kg), and potassium carbonate (77 Kg). The mixture was heated to reflux until reaction completion and solvent was removed leaving 2-chloromethyl-4-phenoxybenzoyl chloride. Methanol was charged and the mixture was heated above 50 °C until reaction completion. Solvent was

removed and replaced with DMF. This solution of the product methyl 2-chloromethyl-4-phenoxybenzoic acid methyl ester in DMF was used directly in the next step (HPLC: 85%).

c) Preparation of 4-hydroxy-7-phenoxyisoquinoline-3-carboxylic acid methyl ester (3a)


[0245]



[0246] A reactor was charged with a solution of 2-chloromethyl-4-phenoxybenzoic acid methyl ester (~8 Kg) in DMF, and stirring was initiated. The reactor was then charged with p-toluenesulfonylglycine methyl ester (66 Kg), potassium carbonate (60 Kg), and sodium iodide (4 Kg). The mixture was heated to at least 50 °C until reaction completion. The mixture was cooled. Sodium methoxide in methanol was charged and the mixture was stirred until reaction completion. Acetic acid and water were added, and the mixture was stirred, filtered and washed with water. Solid was purified by acetone trituration and dried in an oven giving **3a** (Yield from step b): 58%; HPLC: 99.4%). ¹H NMR (200 MHz, DMSO-d₆) δ 11.60 (s, 1 H), 8.74 (s, 1H), 8.32 (d, J = 9.0 Hz, 1 H), 7.60 (dd, J = 2.3 & 9.0 Hz, 1H), 7.49 (m, 3 H), 7.24 (m, 3 H), 3.96 (s, 3 H); MS-(+)-ion M+1 = 296.09

d) Preparation of methyl 1-((dimethylamino)methyl)-4-hydroxy-7-phenoxyisoquinoline-3-carboxylate (3b)


[0247]



[0248] A flask was charged with **3a** (29.5 g) and acetic acid (44.3 g ± 5%), and then stirred. Bis-dimethylaminomethane (12.8 g ± 2%) was slowly added. The mixture was heated to 55 ± 5 °C and maintained until reaction completion. The reaction product was evaluated by MS, HPLC and ¹H NMR. ¹H NMR (200 MHz, DMSO-d₆) δ 11.7 (s, 1 H), 8.38 (d, J = 9.0 Hz, 1 H), 7.61 (dd, J = 9.0, 2.7 Hz, 1 H), 7.49 (m, 3 H), 7.21 (m, 3H), 5.34 (s, 2 H), 3.97 (s, 3 H), 1.98 (s, 3 H); MS-(+)-ion M+1 = 368.12.

e) Preparation of methyl 1-((acetoxymethyl)-4-hydroxy-7-phenoxyisoquinoline-3-carboxylate (3c)

[0249]




[0250] The solution of **3b** from a) above was cooled below 25 °C, at which time acetic anhydride (28.6 g ± 3.5 %) was added to maintain temperature below 50 °C. The resulting mixture was heated to 100 ± 5 °C until reaction completion.

[0251] The solution of **3c** and **3d** from above was cooled to less than 65 ± 5 °C. Water (250 mL) was slowly added. The mixture was then cooled to below 20 ± 5 °C and filtered. The wet cake was washed with water (3 x 50 mL) and added to a new flask. Dichloromethane (90 mL) and water (30 mL) were added, and the resulting mixture was stirred. The dichloromethane layer was separated and evaluated by HPLC.

[0252] The organic layer was added to a flask and cooled 5 ± 5 °C. Morpholine was added and the mixture was stirred until reaction completion. Solvent was replaced with acetone/methanol mixture. After cooling, compound **3c** precipitated and was filtered, washed and dried in an oven (Yield: 81 %, HPLC: >99.7%). ^1H NMR (200 MHz, DMSO- d_6) δ 11.6 (s, 1 H), 8.31 (d, J = 9.0 Hz, 1 H), 7.87 (d, J = 2.3 Hz, 1 H), 7.49 (m, 3 H), 7.24 (m, 3 H), 3.95 (s, 3 H), 3.68 (s, 2H), 2.08 (s, 6 H); MS-(+)-ion $M+1$ = 357.17.

f) Preparation of methyl 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate (3e)


[0253]



[0254] A reactor was charged with **3c** (16.0 g), Pd/C (2.08 g), anhydrous Na_2CO_3 (2.56 g) and ethyl acetate (120 mL). The flask was vacuum-purged with nitrogen (3X) and vacuum-purged with hydrogen (3X). The flask was then pressurized with hydrogen and stirred at about 60 °C until completion of reaction. The flask was cooled to 20-25 °C, the pressure released to ambient, the head space purged with nitrogen three times and mixture was filtered. The filtrate was concentrated. Methanol was added. The mixture was stirred and then cooled. Product precipitated and was filtered and dried in an oven (Yield: 90%, HPLC: 99.7%).

g) Preparation of 2-(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxamido)acetic acid (3f)

[0255]



[0256] 2-(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxamido)acetic acid was prepared from **3e** according to the following procedure.


[0257] A pressure flask was charged with **3e** (30.92 g), glycine (22.52 g), methanol (155 mL), sodium methoxide solution (64.81 g) and sealed (as an alternative, sodium glycinate was used in place of glycine and sodium methoxide). The reaction was heated to about 110 °C until reaction was complete. The mixture was cooled, filtered, washed with methanol, dried under vacuum, dissolved in water and washed with ethyl acetate. The ethyl acetate was removed and to the resulting aqueous layer an acetic acid (18.0 g) solution was added. The suspension was stirred at room temperature, filtered, and the solid washed with water (3 x 30 mL), cold acetone (5-10 °C, 2 x 20 mL), and dried under vacuum to obtain 2-(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxamido)acetic acid (Yield: 86.1%, HPLC: 99.8%).

EXAMPLE 4

Preparation of 2-(4-hydroxy-1-methyl-8-phenoxyisoquinoline-3-carboxamido)acetic acid

a) Preparation of methyl 1-((dimethylamino)methyl)-4-hydroxy-8-phenoxyisoquinoline-3-carboxylate (4b)


[0258]



[0259] A round bottom flask fitted with thermocouple and condenser can be charged with **4a** and acetic acid (about 7 molar equivalents $\pm$ 5%). The suspension of **4a** in acetic acid can be stirred vigorously with magnetic stirring (note: overhead stirring should be done for larger scale work). A slight excess of bis-dimethylaminomethane (about 1.25 molar equivalents) can then be slowly added to the mixture [Note: Reaction is slightly exothermic, 15-20 °C temperature rise can be observed]. After the addition is complete, the mixture can be heated to 55 ± 5 °C and maintained for at least 8 h. The reaction can then be evaluated by HPLC. If the amount of **4a** is greater than 0.5%, the reaction can be stirred for additional 2 hours at 55 ± 5 °C and reevaluated by HPLC.

b) Preparation of methyl 1-((acetoxymethyl)-4-hydroxy-8-phenoxyisoquinoline-3-carboxylate (4c)

[0260]




[0261] The solution of **4b** from Example 4a) can be cooled to below 25 °C, at which time acetic anhydride (about 3 molar equivalents) can be added slowly at a temperature below 50 °C [Note: Reaction is exothermic, 20-25 °C temperature rise can be observed. Rate of addition is important to control the exothermic reaction between acetic anhydride and dimethyl amine **4b**. Excess heat generated will cause unsafe rapid evolution of gaseous dimethyl amine]. After the addition is complete, the mixture can be heated to 100 ± 5 °C for 20-24 hours. The reaction can then be evaluated by HPLC. If **4b** is in an amount greater than 2%, the reaction can be stirred for an additional 2 hours and then reevaluated by HPLC.

[0262] **4d** can be converted to **4c** by the following procedure. The solution of **4c** and **4d** from the above procedure can be cooled to less than 65 ± 5 °C with good mixing. If the reaction temperature goes below 30 °C, the reaction may solidify. Water can be slowly and steadily added (the first half can be added over 1 hour and the rest added over 30 minutes). The mixture can then be cooled and stirred at 20 ± 5 °C for at least 3 hours, at which time the mixture can be filtered and the wet cake washed with water (3X) and added to a round bottom flask fitted with a mechanical stirrer. Dichloromethane and water (3:1 by volume) can be added and the mixture stirred for 30 minutes. The dichloromethane can be separated (without including the interface or aqueous layer) and the solution evaluated by HPLC.

[0263] **4c** can be further purified according to the following procedure. The above solution can be added to a flask, fitted with mechanical stirrer, and cooled to 5 ± 5 °C. Morpholine can be added and the mixture stirred at 5 ± 5 °C for 30-60 minutes and evaluated by HPLC. If the amount of **4d** is greater than 2%, the reaction can be stirred for an additional hour. Once the reaction reached completion, **4c** can be precipitated from cold acetone/methanol solution, filtered, washed and dried under vacuum at 50 ± 5 °C.

c) Preparation of methyl 4-hydroxy-1-methyl-8-phenoxyisoquinoline-3-carboxylate (4e)


[0264]



[0265] A glass lined Parr pressure reactor vessel equipped with a 4-blade impeller can be charged with **4c**, Pd/C (about 0.4 to 0.5 molar equivalents), anhydrous Na₂CO₃ (about 0.5 molar equivalents), and ethyl acetate. The flask can then be vacuum-purged with nitrogen (3X) and vacuum-purged with hydrogen (3X). The flask can then be pressurized with hydrogen to set point 60 psi and stirred at 60 °C for 6-8 hrs until completion of reaction (**4c** <0.5%). The flask can then be cooled to 20-25 °C, the pressure released to ambient, the head space purged with nitrogen three times and filtered through glass microfiber filter paper. The filtrate can be concentrated and precipitated from cold methanol and dried under vacuum at 50 ± 5 °C.

d) Preparation of 2-(4-hydroxy-1-methyl-8-phenoxyisoquinoline-3-carboxamido)acetic acid (4f)

[0266]



[0267] 2-(4-hydroxy-1-methyl-8-phenoxyisoquinoline-3-carboxamido)acetic acid is prepared from **4e** according to the following procedure.


[0268] A pressure glass reaction flask which included top threads for a screw cap lid can be fitted with a magnetic stirrer, charged with **4e**, glycine (about 3 molar equivalents), methanol, and a sodium methoxide solution (with 1.2 molar equivalents NaOCH₃) and sealed. The reaction can then be heated to 110 °C for at least 6 h during which time the reaction forms a yellow suspension. The reaction can then be cooled to 20-25 °C and evaluated by HPLC. The reaction can be continued until less than 1% **4e** remains as determined by HPLC, filtered, washed with methanol, dried under vacuum, dissolved in water and extracted with ethyl acetate to remove impurities to below 0.1 %. The ethyl acetate can be removed and an acetic acid solution (with 3 molar equivalents acetic acid) can be added over one hour. The suspension can be stirred at room temperature for at least 3 hours, filtered, and the solid washed with water (3X), cold acetone (5-10 °C, 2X) and evaluated for impurities by HPLC. If acetone removable impurities are present, the flask can be charged with acetone and refluxed for at least 8 h, slowly cooled to 5-10 °C, stirred for at least 2-3 h, filtered, washed with cold acetone (5-10 °C, 3X) and dried under vacuum to obtain 2-(4-hydroxy-1-methyl-8-phenoxyisoquinoline-3-carboxamido)acetic acid..

EXAMPLE 5


Preparation of 2-[4-hydroxy-1-methyl-7-(4-methoxy-phenoxy)-isoquinoline-3-carboxamido]acetic acid

a) Preparation of methyl 1-((dimethylamino)methyl)-4-hydroxy-7-(4-methoxy-phenoxy)-isoquinoline-3-carboxylate (5b)

[0269]




[0270] A round bottom flask fitted with thermocouple and condenser can be charged with **5a** and acetic acid (about 7 molar equivalents ± 5%). The suspension of **5a** in acetic acid can be stirred vigorously with magnetic stirring (note: overhead stirring should be done for larger scale work). A slight excess of bis-dimethylaminomethane (about 1.25 molar equivalents) can then be slowly added to the mixture [Note: Reaction is slightly exothermic, 15-20 °C temperature rise can be observed]. After the addition is complete, the mixture can be heated to 55 ± 5 °C and maintained for at least 8 h. The reaction can then be evaluated by HPLC. If the amount of **5a** is greater than 0.5%, the reaction can be stirred for additional 2 hours at 55 ± 5 °C and reevaluated by HPLC.

b) Preparation of methyl 1-((acetoxymethyl)-4-hydroxy-7-(4-methoxy-phenoxy)-isoquinoline-3-carboxylate (5c)**[0271]**

[0272] The solution of **5b** from Example 5a) can be cooled to below 25 °C, at which time acetic anhydride (about 3 molar equivalents) can be added slowly at a temperature below 50 °C [Note: Reaction is exothermic, 20-25 °C temperature rise can be observed. Rate of addition is important to control the exothermic reaction between acetic anhydride and dimethyl amine or **5b**. Excess heat generated will cause unsafe rapid evolution of gaseous dimethyl amine]. After the addition is complete, the mixture can be heated to 100 ± 5 °C for 20-24 hours. The reaction can then be evaluated by HPLC. If **5b** is in an amount greater than 2%, the reaction can be stirred for an additional 2 hours and then reevaluated by HPLC.


[0273] **5d** can be converted to **5c** by the following procedure. The solution of **5c** and **5d** from the above procedure can be cooled to less than 65 ± 5 °C with good mixing. If the reaction temperature goes below 30 °C, the reaction may solidify. Water can be slowly and steadily added (the first half can be added over 1 hour and the rest added over 30 minutes). The mixture can then be cooled and stirred at 20±5°C for at least 3 hours, at which time the mixture can be filtered and the wet cake washed with water (3X) and added to a round bottom flask fitted with a mechanical stirrer. Dichloromethane and water (3:1 by volume) can be added and the mixture stirred for 30 minutes. The dichloromethane can be separated (without including the interface or aqueous layer) and the solution evaluated by HPLC.

[0274] **5c** can be further purified according to the following procedure. The above solution can be added to a flask, fitted with mechanical stirrer, and cooled to 5 ± 5 °C. Morpholine can be added and the mixture stirred at 5 ± 5 °C for 30-60 minutes and evaluated by HPLC. If the amount of **5d** is greater than 2%, the reaction can be stirred for an additional hour. Once the reaction reached completion, **5c** can be precipitated from cold acetone/methanol solution, filtered, washed and dried under vacuum at 50 ± 5 °C.

c) Preparation of methyl 4-hydroxy-1-methyl-7-(4-methoxy-phenoxy)-isoquinoline-3-carboxylate (5e)**[0275]**

[0276] A glass lined Parr pressure reactor vessel equipped with a 4-blade impeller can be charged with **5c**, Pd/C (about 0.4 to 0.5 molar equivalents), anhydrous Na₂CO₃ (about 0.5 molar equivalents), and ethyl acetate. The flask can then be vacuum-purged with nitrogen (3X) and vacuum-purged with hydrogen (3X). The flask can then be pressurized with hydrogen to set point 60 psi and stirred at 60 °C for 6-8 hrs until completion of reaction (**5c** <0.5%). The flask can then be cooled to 20-25 °C, the pressure released to ambient, the head space purged with nitrogen three times and filtered through glass microfiber filter paper. The filtrate can be concentrated and precipitated from cold methanol and dried under vacuum at 50 ± 5 °C.

d) Preparation of 2-[4-hydroxy-1-methyl-7-(4-methoxy-phenoxy)-isoquinoline-3-carboxamido] acetic acid (5f)**[0277]**




[0278] 2-[4-Hydroxy-1-methyl-7-(4-methoxy-phenoxy)-isoquinoline-3-carboxamido]acetic acid is prepared from **5e** according to the following procedure.

[0279] A pressure glass reaction flask which included top threads for a screw cap lid can be fitted with a magnetic stirrer, charged with **5e**, glycine (about 3 molar equivalents), methanol, and a sodium methoxide solution (with 1.2 molar equivalents NaOCH_3) and sealed. The reaction can then be heated to 110 °C for at least 6 h during which time the reaction forms a yellow suspension. The reaction can then be cooled to 20-25 °C and evaluated by HPLC. The reaction can be continued until less than 1% **5e** remains as determined by HPLC, filtered, washed with methanol, dried under vacuum, dissolved in water and extracted with ethyl acetate to remove impurities to below 0.1 %. The ethyl acetate can be removed and an acetic acid solution (with 3 molar equivalents acetic acid) can be added over one hour. The suspension can be stirred at room temperature for at least 3 hours, filtered, and the solid washed with water (3X), cold acetone (5-10 °C, 2X) and evaluated for impurities by HPLC. If acetone removable impurities are present, the flask can be charged with acetone and refluxed for at least 8 h, slowly cooled to 5-10 °C, stirred for at least 2-3 h, filtered, washed with cold acetone (5-10 °C, 3X) and dried under vacuum to obtain 2-[4-hydroxy-1-methyl-7-(4-methoxy-phenoxy)-isoquinoline-3-carboxamido]acetic acid.

EXAMPLE 6


Preparation of 2-[4-hydroxy-1-methyl-6-(4-methoxy-phenoxy)-isoquinoline-3-carboxamido]acetic acid

a) Preparation of methyl 1-((dimethylamino)methyl)-4-hydroxy-6-(4-methoxy-phenoxy)-isoquinoline-3-carboxylate (**6b**)



[0281] A round bottom flask fitted with thermocouple and condenser can be charged with **6a** and acetic acid (about 7 molar equivalents $\pm 5\%$). The suspension of **6a** in acetic acid can be stirred vigorously with magnetic stirring (note: overhead stirring should be done for larger scale work). A slight excess of bis-dimethylaminomethane (about 1.25 molar equivalents) can then be slowly added to the mixture [Note: Reaction is slightly exothermic, 15-20 °C temperature rise can be observed]. After the addition is complete, the mixture can be heated to 55 ± 5 °C and maintained for at least 8 h. The reaction can then be evaluated by HPLC. If the amount of **6a** is greater than 0.5%, the reaction can be stirred for additional 2 hours at 55 ± 5 °C and reevaluated by HPLC.

b) Preparation of methyl 1-((acetoxymethyl)-4-hydroxy-6-(4-methoxy-phenoxy)-isoquinoline-3-carboxylate (**6c**)



[0283] The solution of **6b** from Example 6a) can be cooled to below 25 °C, at which time acetic anhydride (about 3 molar


equivalents) can be added slowly at a temperature below 50 °C [Note: Reaction is exothermic, 20-25 °C temperature rise can be observed. Rate of addition is important to control the exothermic reaction between acetic anhydride and dimethyl amine or **6b**. Excess heat generated will cause unsafe rapid evolution of gaseous dimethyl amine]. After the addition is complete, the mixture can be heated to 100 ± 5 °C for 20-24 hours. The reaction can then be evaluated by HPLC. If **6b** is in an amount greater than 2%, the reaction can be stirred for an additional 2 hours and then reevaluated by HPLC.

[0284] **6d** can be converted to **6c** by the following procedure. The solution of **6c** and **6d** from the above procedure can be cooled to less than 65 ± 5 °C with good mixing. If the reaction temperature goes below 30 °C, the reaction may solidify. Water can be slowly and steadily added (the first half can be added over 1 hour and the rest added over 30 minutes). The mixture can then be cooled and stirred at 20±5°C for at least 3 hours, at which time the mixture can be filtered and the wet cake washed with water (3X) and added to a round bottom flask fitted with a mechanical stirrer. Dichloromethane and water (3:1 by volume) can be added and the mixture stirred for 30 minutes. The dichloromethane can be separated (without including the interface or aqueous layer) and the solution evaluated by HPLC.

[0285] **6c** can be further purified according to the following procedure. The above solution can be added to a flask, fitted with mechanical stirrer, and cooled to 5 ± 5 °C. Morpholine can be added and the mixture stirred at 5 ± 5 °C for 30-60 minutes and evaluated by HPLC. If the amount of **6d** is greater than 2%, the reaction can be stirred for an additional hour. Once the reaction reached completion, **6c** can be precipitated from cold acetone/methanol solution, filtered, washed and dried under vacuum at 50 ± 5 °C.

c) Preparation of methyl 4-hydroxy-1-methyl-6-(4-methoxy-phenoxy)-isoquinoline-3-carboxylate (**6e**)


[0286]



[0287] A glass lined Parr pressure reactor vessel equipped with a 4-blade impeller can be charged with **6c**, Pd/C (about 0.4 to 0.5 molar equivalents), anhydrous Na₂CO₃ (about 0.5 molar equivalents), and ethyl acetate. The flask can then be vacuum-purged with nitrogen (3X) and vacuum-purged with hydrogen (3X). The flask can then be pressurized with hydrogen to set point 60 psi and stirred at 60 °C for 6-8 hrs until completion of reaction (**6c** <0.5%). The flask can then be cooled to 20-25 °C, the pressure released to ambient, the head space purged with nitrogen three times and filtered through glass microfiber filter paper. The filtrate can be concentrated and precipitated from cold methanol and dried under vacuum at 50 ± 5 °C.

d) Preparation of 2-[4-hydroxy-1-methyl-6-(4-methoxy-phenoxy)-isoquinoline-3-carboxamido] acetic acid (**6f**)

[0288]



[0289] 2-[4-Hydroxy-1-methyl-6-(4-methoxy-phenoxy)-isoquinoline-3-carboxamido]acetic acid is prepared from **6e** according to the following procedure.

[0290] A pressure glass reaction flask which included top threads for a screw cap lid can be fitted with a magnetic stirrer, charged with **6e**, glycine (about 3 molar equivalents), methanol, and a sodium methoxide solution (with 1.2 molar equivalents NaOCH₃) and sealed. The reaction can then be heated to 110 °C for at least 6 h during which time the reaction forms a yellow suspension. The reaction can then be cooled to 20-25 °C and evaluated by HPLC. The reaction can be continued until less than 1% **6e** remains as determined by HPLC, filtered, washed with methanol, dried under vacuum, dissolved in water and extracted with ethyl acetate to remove impurities to below 0.1 %. The ethyl acetate can be removed and an acetic acid solution (with 3 molar equivalents acetic acid) can be added over one hour. The suspension can be stirred at room temperature for at least 3 hours,


filtered, and the solid washed with water (3X), cold acetone (5-10 °C, 2X) and evaluated for impurities by HPLC. If acetone removable impurities are present, the flask can be charged with acetone and refluxed for at least 8 h, slowly cooled to 5-10 °C, stirred for at least 2-3 h, filtered, washed with cold acetone (5-10 °C, 3X) and dried under vacuum to obtain 2-[4-hydroxy-1-methyl-6-(4-methoxy-phenoxy)-isoquinoline-3-carboxamido]acetic acid.

EXAMPLE 7

Preparation of 2-[4-hydroxy-1-methyl-7-(3,5-difluoro-phenoxy)-isoquinoline-3-carboxamido]acetic acid

a) Preparation of methyl 1-((dimethylamino)methyl)-4-hydroxy-7-(3,5-difluoro-phenoxy)-isoquinoline-3-carboxylate (7b)


[0291]



[0292] A round bottom flask fitted with thermocouple and condenser can be charged with **7a** and acetic acid (about 7 molar equivalents $\pm$ 5%). The suspension of **7a** in acetic acid can be stirred vigorously with magnetic stirring (note: overhead stirring should be done for larger scale work). A slight excess of bis-dimethylaminomethane (about 1.25 molar equivalents) can then be slowly added to the mixture [Note: Reaction is slightly exothermic, 15-20 °C temperature rise can be observed]. After the addition is complete, the mixture can be heated to 55 ± 5 °C and maintained for at least 8 h. The reaction can then be evaluated by HPLC. If the amount of **7a** is greater than 0.5%, the reaction can be stirred for additional 2 hours at 55 ± 5 °C and reevaluated by HPLC.

b) Preparation of methyl 1-((acetoxymethyl)-4-hydroxy-7-(3,5-difluoro-phenoxy)-isoquinoline-3-carboxylate (7c)

[0293]



[0294] The solution of **7b** from Example 7a) can be cooled to below 25 °C, at which time acetic anhydride (about 3 molar equivalents) can be added slowly at a temperature below 50 °C [Note: Reaction is exothermic, 20-25 °C temperature rise can be observed. Rate of addition is important to control the exothermic reaction between acetic anhydride and dimethyl amine or **7b**. Excess heat generated will cause unsafe rapid evolution of gaseous dimethyl amine]. After the addition is complete, the mixture can be heated to 100 ± 5 °C for 20-24 hours. The reaction can then be evaluated by HPLC. If **7b** is in an amount greater than 2%, the reaction can be stirred for an additional 2 hours and then reevaluated by HPLC.


[0295] **7d** can be converted to **7c** by the following procedure. The solution of **7c** and **7d** from the above procedure can be cooled to less than 65 ± 5 °C with good mixing. If the reaction temperature goes below 30 °C, the reaction may solidify. Water can be slowly and steadily added (the first half can be added over 1 hour and the rest added over 30 minutes). The mixture can then be cooled and stirred at 20 ± 5 °C for at least 3 hours, at which time the mixture can be filtered and the wet cake washed with water (3X) and added to a round bottom flask fitted with a mechanical stirrer. Dichloromethane and water (3:1 by volume) can be added and the mixture stirred for 30 minutes. The dichloromethane can be separated (without including the interface or aqueous layer) and the solution evaluated by HPLC.

[0296] **7c** can be further purified according to the following procedure. The above solution can be added to a flask, fitted with

mechanical stirrer, and cooled to 5 ± 5 °C. Morpholine can be added and the mixture stirred at 5 ± 5 °C for 30-60 minutes and evaluated by HPLC. If the amount of **7d** is greater than 2%, the reaction can be stirred for an additional hour. Once the reaction reached completion, **7c** can be precipitated from cold acetone/methanol solution, filtered, washed and dried under vacuum at 50 ± 5 °C.

c) Preparation of methyl 4-hydroxy-1-methyl-7-(3,5-difluoro-phenoxy)-isoquinoline-3-carboxylate (7e**)**


[0297]



[0298] A glass lined Parr pressure reactor vessel equipped with a 4-blade impeller can be charged with **7c**, Pd/C (about 0.4 to 0.5 molar equivalents), anhydrous Na_2CO_3 (about 0.5 molar equivalents), and ethyl acetate. The flask can then be vacuum-purged with nitrogen (3X) and vacuum-purged with hydrogen (3X). The flask can then be pressurized with hydrogen to set point 60 psi and stirred at 60 °C for 6-8 hrs until completion of reaction (**7c** <0.5%). The flask can then be cooled to 20-25 °C, the pressure released to ambient, the head space purged with nitrogen three times and filtered through glass microfiber filter paper. The filtrate can be concentrated and precipitated from cold methanol and dried under vacuum at 50 ± 5 °C.

d) Preparation of 2-[4-hydroxy-1-methyl-7-(3,5-difluoro-phenoxy)-isoquinoline-3-carboxamido]acetic acid (7f**)**

[0299]



[0300] 2-[4-Hydroxy-1-methyl-7-(3,5-difluoro-phenoxy)-isoquinoline-3-carboxamido]acetic acid is prepared from **7e** according to the following procedure.


[0301] A pressure glass reaction flask which included top threads for a screw cap lid can be fitted with a magnetic stirrer, charged with **7e**, glycine (about 3 molar equivalents), methanol, and a sodium methoxide solution (with 1.2 molar equivalents $NaOCH_3$) and sealed. The reaction can then be heated to 110 °C for at least 6 h during which time the reaction forms a yellow suspension. The reaction can then be cooled to 20-25 °C and evaluated by HPLC. The reaction can be continued until less than 1% **7e** remains as determined by HPLC, filtered, washed with methanol, dried under vacuum, dissolved in water and extracted with ethyl acetate to remove impurities to below 0.1 %. The ethyl acetate can be removed and an acetic acid solution (with 3 molar equivalents acetic acid) can be added over one hour. The suspension can be stirred at room temperature for at least 3 hours, filtered, and the solid washed with water (3X), cold acetone (5-10 °C, 2X) and evaluated for impurities by HPLC. If acetone removable impurities are present, the flask can be charged with acetone and refluxed for at least 8 h, slowly cooled to 5-10 °C, stirred for at least 2-3 h, filtered, washed with cold acetone (5-10 °C, 3X) and dried under vacuum to obtain 2-[4-hydroxy-1-methyl-7-(3,5-difluoro-phenoxy)-isoquinoline-3-carboxamido]acetic acid.

EXAMPLE 8

Preparation of 2-[4-hydroxy-1-methyl-6-(3,5-difluoro-phenoxy)-isoquinoline-3-carboxamido]acetic acid

a) Preparation of methyl 1-((dimethylamino)methyl)-4-hydroxy-6-(3,5-difluoro-phenoxy)-isoquinoline-3-carboxylate (8b**)**


[0302]



[0303] A round bottom flask fitted with thermocouple and condenser can be charged with **8a** and acetic acid (about 7 molar equivalents $\pm$ 5%). The suspension of **8a** in acetic acid can be stirred vigorously with magnetic stirring (note: overhead stirring should be done for larger scale work). A slight excess of bis-dimethylaminomethane (about 1.25 molar equivalents) can then be slowly added to the mixture [Note: Reaction is slightly exothermic, 15-20 °C temperature rise can be observed]. After the addition is complete, the mixture can be heated to 55 ± 5 °C and maintained for at least 8 h. The reaction can then be evaluated by HPLC. If the amount of **8a** is greater than 0.5%, the reaction can be stirred for additional 2 hours at 55 ± 5 °C and reevaluated by HPLC.

b) Preparation of methyl 1-((acetoxymethyl)-4-hydroxy-6-(3,5-difluoro-phenoxy)-isoquinoline-3-carboxylate (8c**)**

[0304]




[0305] The solution of **8b** from Example 8a) can be cooled to below 25 °C, at which time acetic anhydride (about 3 molar equivalents) can be added slowly at a temperature below 50 °C [Note: Reaction is exothermic, 20-25 °C temperature rise can be observed. Rate of addition is important to control the exothermic reaction between acetic anhydride and dimethyl amine or **8b**. Excess heat generated will cause unsafe rapid evolution of gaseous dimethyl amine]. After the addition is complete, the mixture can be heated to 100 ± 5 °C for 20-24 hours. The reaction can then be evaluated by HPLC. If **8b** is in an amount greater than 2%, the reaction can be stirred for an additional 2 hours and then reevaluated by HPLC.

[0306] **8d** can be converted to **8c** by the following procedure. The solution of **8c** and **8d** from the above procedure can be cooled to less than 65 ± 5 °C with good mixing. If the reaction temperature goes below 30 °C, the reaction may solidify. Water can be slowly and steadily added (the first half can be added over 1 hour and the rest added over 30 minutes). The mixture can then be cooled and stirred at 20 ± 5 °C for at least 3 hours, at which time the mixture can be filtered and the wet cake washed with water (3X) and added to a round bottom flask fitted with a mechanical stirrer. Dichloromethane and water (3:1 by volume) can be added and the mixture stirred for 30 minutes. The dichloromethane can be separated (without including the interface or aqueous layer) and the solution evaluated by HPLC.

[0307] **8c** can be further purified according to the following procedure. The above solution can be added to a flask, fitted with mechanical stirrer, and cooled to 5 ± 5 °C. Morpholine can be added and the mixture stirred at 5 ± 5 °C for 30-60 minutes and evaluated by HPLC. If the amount of **8d** is greater than 2%, the reaction can be stirred for an additional hour. Once the reaction reached completion, **8c** can be precipitated from cold acetone/methanol solution, filtered, washed and dried under vacuum at 50 ± 5 °C.

c) Preparation of methyl 4-hydroxy-1-methyl-6-(3,5-difluoro-phenoxy)-isoquinoline-3-carboxylate (8e**)**


[0308]



[0309] A glass lined Parr pressure reactor vessel equipped with a 4-blade impeller can be charged with **8c**, Pd/C (about 0.4 to 0.5 molar equivalents), anhydrous Na₂CO₃ (about 0.5 molar equivalents), and ethyl acetate. The flask can then be vacuum-purged with nitrogen (3X) and vacuum-purged with hydrogen (3X). The flask can then be pressurized with hydrogen to set point 60 psi and stirred at 60 °C for 6-8 hrs until completion of reaction (**8c** <0.5%). The flask can then be cooled to 20-25 °C, the pressure released to ambient, the head space purged with nitrogen three times and filtered through glass microfiber filter paper. The filtrate can be concentrated and precipitated from cold methanol and dried under vacuum at 50 ± 5 °C.

d) Preparation of 2-[4-hydroxy-1-methyl-6-(3,5-difluoro-phenoxy)-isoquinoline-3-carboxamido] acetic acid (8f**)**

[0310]



[0311] 2-[4-hydroxy-1-methyl-6-(3,5-difluoro-phenoxy)-isoquinoline-3-carboxamido]acetic acid is prepared from **8e** according to the following procedure.

[0312] A pressure glass reaction flask which included top threads for a screw cap lid can be fitted with a magnetic stirrer, charged with **8e**, glycine (about 3 molar equivalents), methanol, and a sodium methoxide solution (with 1.2 molar equivalents NaOCH₃) and sealed. The reaction can then be heated to 110 °C for at least 6 h during which time the reaction forms a yellow suspension. The reaction can then be cooled to 20-25 °C and evaluated by HPLC. The reaction can be continued until less than 1% **8e** remains as determined by HPLC, filtered, washed with methanol, dried under vacuum, dissolved in water and extracted with ethyl acetate to remove impurities to below 0.1 %. The ethyl acetate can be removed and an acetic acid solution (with 3 molar equivalents acetic acid) can be added over one hour. The suspension can be stirred at room temperature for at least 3 hours, filtered, and the solid washed with water (3X), cold acetone (5-10 °C, 2X) and evaluated for impurities by HPLC. If acetone removable impurities are present, the flask can be charged with acetone and refluxed for at least 8 h, slowly cooled to 5-10 °C, stirred for at least 2-3 h, filtered, washed with cold acetone (5-10 °C, 3X) and dried under vacuum to obtain 2-[4-hydroxy-1-methyl-6-(3,5-difluoro-phenoxy)-isoquinoline-3-carboxamido]acetic acid.

EXAMPLE 9

Biological Testing

[0313] The compounds and methods of the invention can be used for the synthesis of various isoquinoline compounds. Such compounds are known to be useful for inhibiting HIF hydroxylase activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF), and can be used to treat and prevent HIF-associated conditions and disorders (see, e.g., U.S. Patent No. 7,323,475, U.S. Publication No. 2007/0004627, U.S. Publication No. 2006/0276477, and U.S. Publication No. 2007/0259960, incorporated by reference herein).

[0314] The biological activity of exemplary substituted isoquinoline compounds may be assessed using any conventionally known methods. In particular embodiments, cells derived from animal tissues, preferably human tissues, capable of expressing erythropoietin when stimulated by compounds of the invention are cultured for the *in vitro* production of endogenous proteins. Cells contemplated for use in such methods include, but are not limited to, cells derived from hepatic, hematopoietic, renal, and neural tissues.

[0315] Cell culture techniques are generally available in the art and include any method that maintains cell viability and facilitates expression of endogenous proteins. Cells are typically cultured in a growth medium optimized for cell growth, viability, and protein production. Cells may be in suspension or attached to a substrate, and medium may be supplied in batch feed or continuous flow-through regimens. Compounds of the invention are added to the culture medium at levels that stimulate erythropoietin production without compromising cell viability. Erythropoietin produced by the cells is secreted into the culture medium. The medium is then collected and the erythropoietin is purified using methods known to those of skill in the art. (See, e.g., Lai et al. (1987) U.S. Pat. No. 4,667,016; and Egrie (1985) U.S. Pat. No. 4,558,006.)

[0316] Suitable assay methods are well known in the art. The following are presented only as examples and are not intended to be limiting.

Cell-based HIF α stabilization assay

[0317] Human cells (e.g., Hep3B cells from hepatocellular tissue) derived from various tissues were separately seeded into 35 mm culture dishes, and grown at 37 °C, 20 % O₂, 5 % CO₂ in standard culture medium, e.g., DMEM (Dulbecco's modification of Eagle's medium), 10 % FBS (fetal bovine serum). When cell layers reach confluence, the media was replaced with OPTI-MEM media (Invitrogen Life Technologies, Carlsbad CA), and cell layers were incubated for approximately 24 hours in 20 % O₂, 5 % CO₂ at 37 °C. Compound or 0.013 % DMSO (dimethyl sulfoxide) was then added to existing medium and incubation was continued overnight.

[0318] Following incubation, the media was removed, centrifuged, and stored for analysis (see Cell-based VEGF and EPO assays below). The cells were washed two times in cold phosphate buffered saline (PBS) and then lysed in 1 mL of 10 mM Tris (pH 7.4), 1 mM EDTA, 150 mM NaCl, 0.5 % IGEPAL (Sigma-Aldrich, St. Louis MO), and a protease inhibitor mix (Roche Molecular Biochemicals) for 15 minutes on ice. Cell lysates were centrifuged at 3,000 xg for 5 minutes at 4 °C, and the cytosolic fractions (supernatant) were collected. The nuclei (pellet) were resuspended and lysed in 100 μ L of 20 mM HEPES (pH 7.2), 400 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, and a protease mix (Roche Molecular Biochemicals), centrifuged at 13,000 xg for 5 minutes at 4 °C, and the nuclear protein fractions (supernatant) were collected.

[0319] The Nuclear protein fractions collected were analyzed for HIF-1 α using a QUANTIKINE immunoassay (R&D Systems, Inc., Minneapolis MN) according to the manufacturer's instructions.

Cell-based EPO assay

[0320] Hep3B cells (human hepatocellular carcinoma cells from ATCC, cat # HB-8064) were plated at 25,000 cells per well 96 well plates. The next day, the cells were washed once with DMEM (Cellgro, cat # 10-013-CM) + 0.5% fetal bovine serum (Cellgro, cat # 35-010-C) and incubated with various concentrations of compound or vehicle control (0.15% DMSO) in DMEM + 0.5% fetal bovine serum for 72 hours. Cell free culture supernatants were generated by transfer to a conical bottom 96 well plate and centrifugation for 5 minutes at 2000rpm. The supernatant was quantitated for EPO using a human EPO ELISA kit (R&D Systems, cat # DEP 00).

[0321] The EPO values for the compounds reported herein (e.g., Table 1) are the measured value for cells plus compound minus the value for the vehicle control for the same cell preparation. The EPO values for the vehicle control for the cell preparations used in experiments reported herein varied from 0-12.5 mIU/ml.

HIF-PH assay

[0322] Ketoglutaric acid α -[1-¹⁴C]-sodium salt, alpha-ketoglutaric acid sodium salt, and HPLC purified peptide were obtained from commercial sources, e.g., Perkin-Elmer (Wellesley MA), Sigma-Aldrich, and SynPep Corp. (Dublin CA), respectively. Peptides for use in the assay were fragments of HIF α as described above or as disclosed in International Publication WO 2005/118836, incorporated by reference herein. For example, a HIF peptide for use in the HIF-PH assay was [methoxycoumarin]-DLLEALAPYIPADDDFQL-amide. HIF-PH, e.g., HIF-PH2 (also known as EGLN1 or PHD2), was expressed in, e.g., insect H5 cells, and partially purified, e.g., through a SP ion exchange chromatography column. Enzyme activity was determined by capturing ¹⁴CO₂ using an assay described by Kivirikko and Myllyla (1982, Methods Enzymol. 82:245-304). Assay reactions contained 50 mM HEPES (pH 7.4), 100 μ M α -ketoglutaric acid sodium salt, 0.30 μ Ci/mL α -ketoglutaric acid α -[1-¹⁴C]-sodium salt, 40 μ M FeSO₄, 1 mM ascorbate, 1541.8 units/mL Catalase, with or without 50 μ M peptide substrate and various concentrations of compound of the invention. Reactions were initiated by addition of HIF-PH enzyme.

[0323] The peptide-dependent percent turnover was calculated by subtracting percent turnover in the absence of peptide from percent turnover in the presence of substrate peptide. Percent inhibition and IC₅₀ were calculated using peptide-dependent

percent turnover at given inhibitor concentrations. Calculation of IC₅₀ values for each inhibitor was conducted using GraFit software (Erithacus Software Ltd., Surrey UK). The results were summarized in Table 1.

[0324] Table 1 below was intended to demonstrate the pharmacological utility of exemplary substituted isoquinoline compounds. By inhibiting HIF prolyl hydroxylase enzymes, substituted isoquinoline compounds stabilize HIF α , which then combines with HIF β to form an active transcription factor that increases expression of numerous genes involved in response to hypoxic and ischemic conditions, including erythropoietin (EPO).

Table 1.

Example No.	Compound No.	IC ₅₀ PHD2 (μ M)	Cell EPO* (mIU/ml)
1	1f	7.9	98.6
2	2f	3.5	78
3	3f	2.1	182
4	4f	1.4	52
5	5f	2.2	209
6	6f	5.2	191
7	7f	2.2	225
8	8f	not determined	105
*Cell EPO measured at 30 μ M compound in DMSO compared to DMSO only control			

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [US61672191B \[0001\]](#)
- [US6693730A \[0006\]](#)
- [US7629357B \[0007\] \[0007\] \[0007\] \[0009\] \[0094\]](#)
- [US7928120B \[0007\] \[0007\]](#)
- [US7323475B \[0095\] \[0166\] \[0197\] \[0214\] \[0215\] \[0216\] \[0313\]](#)
- [US20070004627A \[0313\]](#)
- [US20060276477A \[0313\]](#)
- [US20070259960A \[0313\]](#)
- [US4667016A \[0315\]](#)
- [US4558006A \[0315\]](#)
- [WO2005118636A \[0322\]](#)


Non-patent literature cited in the description

- **ROBINSON et al.** Gastroenterology, 2008, vol. 134, 1145-155 [\[0003\]](#)
- **ROSENBERGER et al.** Nephrol Dial Transplant, 2008, vol. 23, 113472-3478 [\[0003\]](#)
- **CASWELL et al.** Heterocycl Chem, 1966, 3328-332 [\[0004\]](#)
- **SUZUKI et al.** Synthesis, 1978, 461-462 [\[0005\]](#)
- Remington's Pharmaceutical Sciences Mack Publishing Co. 19900000 [\[0016\]](#)


- Methods In Enzymology Academic Press, Inc. [0019]
- Handbook of Experimental Immunology Blackwell Scientific Publications 19860000 vol. I-IV, [0018]
- Molecular Cloning: A Laboratory Manual Cold Spring Harbor Laboratory Press 19890000 vol. I-III, [0018]
- Short Protocols in Molecular Biology John Wiley & Sons 19990000 [0018]
- Molecular Biology Techniques: An Intensive Laboratory Course Academic Press 19980000 [0018]
- PCR (Introduction to Biotechniques Series) Springer Verlag 19970000 [0018]
- **BERGE et al.** Journal of Pharmaceutical Science, 1977, vol. 66, 1-19 [0077]
- **T. W. GREENE. G. M. WUTS** Protecting Groups in Organic Synthesis Wiley 19990000 [0086]
- **T. W. GREENE. G. M. WUTS** Protecting Groups in Organic Synthesis Wiley 19990000 [0097]
- **FIESER FIESER'S** Reagents for Organic Synthesis John Wiley, and Sons 19910000 vol. 1-15, [0099]
- Rodd's Chemistry of Carbon Compounds Elsevier Science Publishers 19890000 vol. 1-5, [0099]
- Organic Reactions John Wiley, and Sons 19910000 vol. 1-40, [0099]
- March's Advanced Organic Chemistry John Wiley, and Sons 20010000 [0099]
- Larock's Comprehensive Organic Transformations VCH Publishers Inc. 19890000 [0099]
- **KIVIRIKKOMYLLYLA** Methods Enzymol., 1982, vol. 82, 245-304 [0322]

Patentkrav


1. Fremgangsmåde til fremstilling af en forbindelse med formel I eller en stereoisomer eller blanding af stereoisomerer deraf:



5 fremgangsmåden omfatter at kontakte en forbindelse med formel II:



med en forbindelse med formel III:



under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med
10 formel I; hvor

Z er O, NR¹, eller S;

R¹ er valgt fra gruppen bestående af hydrogen og alkyl;

R² er valgt fra gruppen bestående af hydrogen og alkyl der er usubstitueret
eller substitueret med én eller flere substituent uafhængigt valgt fra
15 gruppen bestående af cycloalkyl, heterocyclyl, aryl, og heteroaryl;

R³ og R⁴ er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl,
substitueret alkyl, cycloalkyl, substitueret cycloalkyl, heterocyclyl,
substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, substitueret
heteroaryl, halo, hydroxy, cyano, -S(O)_n-N(R⁸)-R⁸, -NR⁸C(O)NR⁸R⁸, og
20 -X¹R⁸;

hvor X¹ er oxygen, -S(O)_n-, eller -NR⁹-;

n er 0, 1, eller 2;

hver R^8 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, cycloalkyl, substitueret cycloalkyl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl forudsat at når X^1 er $-SO-$ eller $-SO_2-$, så er R^8 ikke hydrogen;
 5 og

R^9 er valgt fra gruppen bestående af hydrogen, alkyl, og aryl;

eller R^3 og R^4 sammen med de carbonatomer der er bundet dertil, danner cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, eller substitueret heteroaryl;

10 R^5 og R^6 er uafhængigt valgt fra gruppen bestående af hydrogen, halo, alkyl, substitueret alkyl, alkoxy, substitueret alkoxy, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl og $-X^2R^{10}$;
 hvor X^2 er oxygen, $-S(O)_n-$, eller $-NR^{13}-$;

n er 0, 1, eller 2;


15 R^{10} er valgt fra gruppen bestående af alkyl, substitueret alkyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl; og

R^{13} er valgt fra gruppen bestående af hydrogen, alkyl, og aryl; eller når X^2 er $-NR^{13}-$, så R^{10} og R^{13} , sammen med det nitrogenatom til hvilket de er
 20 bundet, kan være forbundet med danner en heterocyclyl- eller substitueret heterocyclylgruppe; og

hver R^{11} er uafhængigt valgt fra alkyl, benzyl og aryl, eller to R^{11} sammen med det nitrogenatom til hvilket de er bundet danner en 4-8-leddet heterocyclyl eller en heteroaryl.


25

2. Fremgangsmåden ifølge krav 1 til fremstilling af en forbindelse med formel IA eller en stereoisomer eller blanding af stereoisomerer deraf:




IA

omfatter at kontakte en forbindelse med formel IIA:



IIA

med en forbindelse med formel III:



under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel IA; hvor

10 R^2 er valgt fra gruppen bestående af hydrogen og alkyl der er usubstitueret eller substitueret med én eller flere substituenten uafhængigt valgt fra gruppen bestående af cycloalkyl, heterocyclyl, aryl, og heteroaryl;

15 R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, halo, hydroxy, cyano, $-S(O)_n-N(R^8)-R^8$ hvor n er 0, 1, eller 2, $-NR^8C(O)NR^8R^8$, og $-X^1R^8$ hvor X^1 er oxygen, $-S(O)_n$ eller $-NR^9-$ hvor n er 0, 1, eller 2, eller R^3 , R^4 sammen med carbonatomet bundet dertil, danner cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, eller substitueret heteroaryl;

20 R^5 og R^6 er uafhængigt valgt fra gruppen bestående af hydrogen, halo, alkyl, substitueret alkyl, alkoxy, substitueret alkoxy, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl og $-X^2R^{10}$ hvor X^2 er oxygen, $-S(O)_n$ eller $-NR^{13}-$ hvor n er 0, 1, eller 2, eller når X^2 er $-NR^{13}-$, så kan R^{13} og R^{10} , sammen med det nitrogenatom til hvilket de er bundet, være forbundet til at danne heterocyclyl eller substitueret heterocyclylgruppe;

hver R^8 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, cycloalkyl, substitueret cycloalkyl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl forudsat at når X^1 er $-SO-$ eller $-SO_2-$ så er R^8 ikke hydrogen;

- 5 R^9 og R^{13} er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, og aryl;


R^{10} er valgt fra gruppen bestående af alkyl, substitueret alkyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl; og

- 10 hver R^{11} er uafhængigt valgt fra alkyl, benzyl og aryl, eller to R^{11} sammen med det nitrogenatom til hvilket de er bundet danner en 4-8-leddet heterocyclyl eller en heteroaryl.


3. Fremgangsmåden ifølge krav 1 eller krav 2, hvor

- 15 (i) reaktionsbetingelserne omfatter en syre, såsom iseddikesyre; eller
- (ii) omsætningen udføres ved en temperatur større end ca. 30°C , såsom fra ca. 50°C til ca. 60°C ; eller
- (iii) R^{11} er C_1 til C_4 alkyl.


- 20 4. Fremgangsmåde til fremstilling af en forbindelse med formel IV eller en stereoisomer eller blanding af stereoisomerer deraf:




omfatter at kontakte en forbindelse med formel I:




med en forbindelse med formel




efterfulgt af en forbindelse med formel



en forbindelse med formel $R^{12}-X^3$ efterfulgt af en forbindelse med formel



eller en forbindelse med formel V:



- 10 under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel IV; hvor

Z er O, NR^1 eller S;

R^1 er valgt fra gruppen bestående af hydrogen og alkyl;

- 15 R^2 er valgt fra gruppen bestående af hydrogen og alkyl der er usubstitueret eller substitueret med én eller flere substituenten uafhængigt valgt fra gruppen bestående af cycloalkyl, heterocyclyl, aryl, og heteroaryl;

- 20 R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, halo, hydroxy, cyano, $-S(O)_n-N(R^8)-R^8$ hvor n er 0, 1, eller 2, $-NR^8C(O)NR^8R^8$, og $-X^1R^8$ hvor X^1 er oxygen, $-S(O)_n$ eller $-NR^9-$ hvor n er 0, 1, eller 2, eller R^3 , R^4 sammen med carbonatomet bundet dertil, danner

cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, eller substitueret heteroaryl;

5 R^5 og R^6 er uafhængigt valgt fra gruppen bestående af hydrogen, halo, alkyl, substitueret alkyl, alkoxy, substitueret alkoxy, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl og $-X^2R^{10}$ hvor X^2 er oxygen, $-S(O)_n$ eller $-NR^{13}-$ hvor n er 0, 1, eller 2, eller når X^2 er $-NR^{13}-$, så kan R^{13} og R^{10} , sammen med det nitrogenatom til hvilket de er bundet, være forbundet til at danne en heterocyclyl eller substitueret heterocyclylgruppe;

10 hver R^8 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, cycloalkyl, substitueret cycloalkyl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl forudsat at når X^1 er $-SO-$ eller $-SO_2-$, så er R^8 ikke hydrogen;

R^9 og R^{13} er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, og aryl;

15 R^{10} er valgt fra gruppen bestående af alkyl, substitueret alkyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl;


20 hver R^{11} er uafhængigt valgt fra alkyl, benzyl og aryl, eller to R^{11} sammen med det nitrogenatom til hvilket de er bundet danner en 4-8-leddet heterocyclyl eller en heteroaryl;

hver R^{12} er uafhængigt valgt fra gruppen bestående af alkyl, aryl, heteroaryl, og heterocyclyl, eller når to R^{12} er til stede, to R^{12} sammen med carbonatomet til hvilket de er bundet danner en 4-8-leddet heterocyclyl; og


X^3 er halo.

25


5. Fremgangsmåden ifølge krav 4 til fremstilling af en forbindelse med formel IVA eller en stereoisomer eller blanding af stereoisomerer deraf:



omfattende at kontakte en forbindelse med formel IA:



med en forbindelse med formel V:



under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel IVA; hvor

10 R^2 er valgt fra gruppen bestående af hydrogen og alkyl der er usubstitueret eller substitueret med én eller flere substituenten uafhængigt valgt fra gruppen bestående af cycloalkyl, heterocyclyl, aryl, og heteroaryl;

15 R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, halo, hydroxy, cyano, $-S(O)_n-N(R^8)-R^8$ hvor n er 0, 1, eller 2, $-NR^8C(O)NR^8R^8$, og $-X^1R^8$ hvor X^1 er oxygen, $-S(O)_n-$ eller $-NR^9-$ hvor n er 0, 1, eller 2, eller R^3 , R^4 sammen med carbonatomet bundet dertil, danner cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, eller substitueret heteroaryl;

20 R^5 og R^6 er uafhængigt valgt fra gruppen bestående af hydrogen, halo, alkyl, substitueret alkyl, alkoxy, substitueret alkoxy, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl og $-X^2R^{10}$ hvor X^2 er oxygen, $-S(O)_n-$ eller $-NR^{13}-$ hvor n er 0, 1, eller 2, eller når X^2 er $-NR^{13}-$, så kan R^{13} og R^{10} , sammen med det nitrogenatom til hvilket de er bundet, være forbundet til at danne heterocyclyl eller substitueret heterocyclylgruppe;

hver R^8 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, cycloalkyl, substitueret cycloalkyl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl forudsat at når X^1 er $-SO-$ eller $-SO_2-$ så er R^8 ikke hydrogen;

5 R^9 og R^{13} er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, og aryl;

R^{10} er valgt fra gruppen bestående af alkyl, substitueret alkyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl;

10 hver R^{11} er uafhængigt valgt fra alkyl, benzyl og aryl, eller to R^{11} sammen med det nitrogenatom til hvilket de er bundet danner en 4-8-leddet heterocyclyl eller heteroaryl; og

hver R^{12} er uafhængigt valgt fra gruppen bestående af alkyl, aryl, heteroaryl, og heterocyclyl, eller to R^{12} sammen med carbonatomet til
15 hvilket de er bundet danner en 4-8-leddet heterocyclyl.

6. Fremgangsmåden ifølge krav 4 eller krav 5, hvor

(i) reaktionsbetingelserne omfatter en forbindelse med formel V; eller

(ii) omsætningen ledes under en inert atmosfære, fx under en
20 nitrogenatmosfære; eller


(iii) reaktionsbetingelserne er vandfrie reaktionsbetingelser; eller

(iv) omsætningen udføres ved en temperatur større end ca. 30°C , såsom ved en temperatur på ca. 100°C ; eller


(v) R^{11} og R^{12} er C_1 til C_4 alkyl, såsom methyl; eller

25 (vi) reaktionsbetingelserne omfatter en forbindelse med formel V hvor R^{12} er C_1 til C_4 alkyl; og hvor omsætningen udføres ved en temperatur på ca. 100°C , eventuelt under en nitrogenatmosfære.

7. Fremgangsmåden ifølge krav 4 eller krav 5, hvor reaktionsbetingelserne yderligere omfatter omdannelse af en forbindelse med formel VII til en forbindelse med formel IV;




eller omdannelse af en forbindelse med formel VIIA til en forbindelse med formel IVA.




og eventuelt hvor

- 10 (i) reaktionsbetingelserne omfatter en amin, såsom morpholin; eller
- (ii) omsætningen udføres i dichlormethan; eller
- (iii) omsætningen udføres ved en temperatur under 25°C, såsom fra ca. 0°C til ca. 10°C; eller
- (iv) reaktionsbetingelserne omfatter morpholin; og omsætningen udføres i
- 15 dichlormethan og ved en temperatur på fra ca. 0°C til ca. 10°C.

8. Fremgangsmåde til fremstilling af en forbindelse med formel VI eller en stereoisomer eller blanding af stereoisomerer deraf:



omfattende omdannelse af en forbindelse med formel IV:



under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel VI; hvor

5 Z er O, NR¹ eller S;

R¹ er valgt fra gruppen bestående af hydrogen og alkyl;

R² er valgt fra gruppen bestående af hydrogen og alkyl der er usubstitueret eller substitueret med én eller flere substituent uafhængigt valgt fra gruppen bestående af cycloalkyl, heterocyclyl, aryl, og heteroaryl;

10 R³ og R⁴ er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, halo, hydroxy, cyano, -S(O)_n-N(R⁸)-R⁸ hvor n er 0, 1, eller 2, -NR⁸C(O)NR⁸R⁸, og -X¹R⁸ hvor X¹ er oxygen, -S(O)_n eller -NR⁹- hvor n er 0, 1, eller 2, eller R³, R⁴ sammen med carbonomet afhængigt deraf, danner
15 cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, eller substitueret heteroaryl;

R⁵ og R⁶ er uafhængigt valgt fra gruppen bestående af hydrogen, halo, alkyl, substitueret alkyl, alkoxy, substitueret alkoxy, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl og -X²R¹⁰ hvor X² er oxygen, -S(O)_n eller
20 -NR¹³- hvor n er 0, 1, eller 2, eller når X² er -NR¹³-, så kan R¹³ og R¹⁰, sammen med det nitrogenatom til hvilket de er bundet, være forbundet til at danne heterocyclyl eller substitueret heterocyclylgruppe;

hver R⁸ er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, cycloalkyl, substitueret cycloalkyl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl forudsat at når X¹ er -SO- eller -SO₂-, så er R⁸ ikke hydrogen;


25

R^9 og R^{13} er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, og aryl; og


R^{10} er valgt fra gruppen bestående af alkyl, substitueret alkyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl; og

hver R^{12} er uafhængigt valgt fra gruppen bestående af alkyl, aryl, heteroaryl, og heterocyclyl.

9. Fremgangsmåden ifølge krav 8 til fremstilling af en forbindelse med formel VIA eller en stereoisomer eller blanding af stereoisomerer deraf:



omfattende omdannelse af en forbindelse med formel IVA:



under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel VIA; hvor

R^2 er valgt fra gruppen bestående af hydrogen og alkyl der er usubstitueret eller substitueret med én eller flere substituent uafhængigt valgt fra gruppen bestående af cycloalkyl, heterocyclyl, aryl, og heteroaryl;

R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, halo, hydroxy, cyano, $-S(O)_n-N(R^8)-R^8$ hvor n er 0, 1, eller 2, $-NR^8C(O)NR^8R^8$, og $-X^1R^8$ hvor X^1 er oxygen, $-S(O)_n-$ eller $-NR^9-$ hvor n er 0, 1, eller 2, eller R^3 , R^4 sammen med carbonatomet bundet dertil, danner

cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, eller substitueret heteroaryl;

5 R^5 og R^6 er uafhængigt valgt fra gruppen bestående af hydrogen, halo, alkyl, substitueret alkyl, alkoxy, substitueret alkoxy, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl og $-X^2R^{10}$ hvor X^2 er oxygen, $-S(O)_n-$ eller $-NR^{13}-$ hvor n er 0, 1, eller 2, eller når X^2 er $-NR^{13}-$, så kan R^{13} og R^{10} , sammen med det nitrogenatom til hvilket de er bundet, være forbundet til at danne heterocyclyl eller substitueret heterocyclylgruppe;

10 hver R^8 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, cycloalkyl, substitueret cycloalkyl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl forudsat at når X^1 er $-SO-$ eller $-SO_2-$, så er R^8 ikke hydrogen;

R^9 og R^{13} er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, og aryl; og

15 R^{10} er valgt fra gruppen bestående af alkyl, substitueret alkyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl; og

hver R^{12} er uafhængigt valgt fra gruppen bestående af alkyl, aryl, heteroaryl, og heterocyclyl.

20

10. Fremgangsmåden ifølge krav 8 eller krav 9, hvor

(i) reaktionsbetingelserne omfatter hydrogen; eller

(ii) reaktionsbetingelserne omfatter en base, fx natriumcarbonat;

(iii) reaktionsbetingelserne omfatter ethylacetat;

25 (iv) reaktionsbetingelserne omfatter en katalysator, fx Pd/C; eller


(v) reaktionsbetingelserne omfatter en tilstand under tryk, fx en tilstand under tryk ved ca. 60 psi; eller

(vi) reaktionsbetingelserne omfatter hydrogen, natriumcarbonat, ethylacetat, Pd/C, og en tilstand under tryk; eller

(vii) reaktionsbetingelserne omfatter hydrogen, natriumcarbonat, ethylacetat, Pd/C, og en tilstand under tryk ved ca. 60 psi;


5 (viii) R¹² er C₁ til C₄ alkyl, fx methyl.

11. Fremgangsmåde til fremstilling af en forbindelse med formel VI eller en stereoisomer eller blanding af stereoisomerer deraf:




10 fremgangsmåden omfattende trinnene at:

a) kontakte en forbindelse med formel II med en forbindelse med formel III




under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel I:




15

b) kontakte en forbindelse med formel I med en forbindelse med formel




efterfulgt af en forbindelse med formel




14


en forbindelse med formel $R^{12}-X^3$ efterfulgt af en forbindelse med formel




eller en forbindelse med formel V:



- 5 under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel IV:



c) eventuelt omdanne en forbindelse med formel VII:



- 10 under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel IV; og

d) omdanne en forbindelse med formel IV under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel VI;
hvor

- 15 Z er O, NR^1 eller S;

R^1 er valgt fra gruppen bestående af hydrogen og alkyl;

R^2 er valgt fra gruppen bestående af hydrogen og alkyl der er usubstitueret eller substitueret med én eller flere substituent uafhængigt valgt fra gruppen bestående af cycloalkyl, heterocyclyl, aryl, og heteroaryl;

5 R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, halo, hydroxy, cyano, $-S(O)_n-N(R^8)-R^8$ hvor n er 0, 1, eller 2, $-NR^8C(O)NR^8R^8$, og $-X^1R^8$ hvor X^1 er oxygen, $-S(O)_n-$ eller $-NR^9-$ hvor n er 0, 1, eller 2, eller R^3 , R^4 sammen med carbonatomet bundet dertil, danner cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, eller substitueret heteroaryl;

10 R^5 og R^6 er uafhængigt valgt fra gruppen bestående af hydrogen, halo, alkyl, substitueret alkyl, alkoxy, substitueret alkoxy, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl og $-X^2R^{10}$ hvor X^2 er oxygen, $-S(O)_n-$ eller $-NR^{13}-$ hvor n er 0, 1, eller 2, eller når X^2 er $-NR^{13}-$, så kan R^{13} og R^{10} , sammen med det nitrogenatom til hvilket de er bundet, være forbundet til at danne heterocyclyl eller substitueret heterocyclylgruppe;

15 hver R^8 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, cycloalkyl, substitueret cycloalkyl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl forudsat at når X^1 er $-SO-$ eller $-SO_2-$ så er R^8 ikke hydrogen;

20 R^9 og R^{13} er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, og aryl; og


R^{10} er valgt fra gruppen bestående af alkyl, substitueret alkyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl;

25 hver R^{11} er uafhængigt valgt fra alkyl, benzyl og aryl, eller to R^{11} sammen med det nitrogenatom til hvilket de er bundet danner en 4-8-leddet heterocyclyl eller en heteroaryl;

hver R^{12} er uafhængigt valgt fra gruppen bestående af alkyl, aryl, heteroaryl, og heterocyclyl, eller når to R^{12} er til stede, to R^{12} sammen med carbonatomet til hvilket de er bundet danner en 4-8-leddet heterocyclyl; og


30 X^3 er halo.

12. Fremgangsmåden ifølge krav 11 til fremstilling af en forbindelse med formel VIA eller en stereoisomer eller blanding af stereoisomerer deraf:




5 fremgangsmåden omfattende trinnene at:

a) kontakte en forbindelse med formel IIA med en forbindelse med formel III




under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel IA:

10




b) kontakte en forbindelse med formel IA med en forbindelse med formel V




under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel IVA:

15



c) eventuelt omdanne en forbindelse med formel VIIA:



under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel IVA; og

- 5 d) omdanne en forbindelse med formel IVA under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel VIA; hvor

10 R^2 er valgt fra gruppen bestående af hydrogen og alkyl der er usubstitueret eller substitueret med én eller flere substituent uafhængigt valgt fra gruppen bestående af cycloalkyl, heterocyclyl, aryl, og heteroaryl;

15 R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, halo, hydroxy, cyano, $-S(O)_n-N(R^8)-R^8$ hvor n er 0, 1, eller 2, $-NR^8C(O)NR^8R^8$, og $-X^1R^8$ hvor X^1 er oxygen, $-S(O)_n-$ eller $-NR^9-$ hvor n er 0, 1, eller 2, eller R^3 , R^4 sammen med carbonatomet bundet dertil, danner cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, eller substitueret heteroaryl;

20 R^5 og R^6 er uafhængigt valgt fra gruppen bestående af hydrogen, halo, alkyl, substitueret alkyl, alkoxy, substitueret alkoxy, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl og $-X^2R^{10}$ hvor X^2 er oxygen, $-S(O)_n-$ eller $-NR^9-$ hvor n er 0, 1, eller 2, eller når X^2 er $-NR^{13}-$, så kan R^{13} og R^{10} , sammen med det nitrogenatom til hvilket de er bundet, være forbundet til at danne heterocyclyl eller substitueret heterocyclylgruppe;

25 hver R^8 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, cycloalkyl, substitueret cycloalkyl,

heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl forudsat at når X^1 er $-SO-$ eller $-SO_2-$, så er R^8 ikke hydrogen;

R^9 og R^{13} er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, og aryl; og

- 5 R^{10} er valgt fra gruppen bestående af alkyl, substitueret alkyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl;

- 10 hver R^{11} er uafhængigt valgt fra alkyl, benzyl og aryl, eller to R^{11} sammen med det nitrogenatom til hvilket de er bundet danner en 4-8-leddet heterocyclyl eller en heteroaryl; og

hver R^{12} er uafhængigt valgt fra gruppen bestående af alkyl, aryl, heteroaryl, og heterocyclyl, eller to R^{12} sammen med carbonatomet til hvilket de er bundet danner en 4-8-leddet heterocyclyl.

- 15 **13.** Fremgangsmåden ifølge krav 11 eller krav 12, hvor

(i) reaktionsbetingelserne af trinnene a) og b) omfatter en syre; eller


(ii) R^{11} og R^{12} er C_1 til C_4 alkyl; eller

(iii) R^{11} og R^{12} er C_1 til C_4 alkyl, og R^3 , R^5 og R^6 er hydrogen; eller

(iv) R^{11} og R^{12} er C_1 til C_4 alkyl, og R^4 , R^5 og R^6 er hydrogen; eller


- 20 (v) R^{11} og R^{12} er methyl.

14. Fremgangsmåden ifølge krav 11 til fremstilling af en forbindelse med formel VIC eller en stereoisomer eller blanding af stereoisomerer deraf:




omfattende trinnene at:


a) kontakte en forbindelse med formel IIC med en forbindelse med formel IIIA




under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel IC:




10 b) kontakte en forbindelse med formel IC med en forbindelse med formel VA



under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel IVC:




15 c) eventuelt omdanne en forbindelse med formel VIIC:



under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel IVC; og

d) omdanne en forbindelse med formel IVC under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel VIC; og eventuelt

- 5 e) kontakte en forbindelse med formel VIC med glycin under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel XC:



eller en stereoisomer eller blanding af stereoisomerer deraf;

10 hvor

R^2 er valgt fra gruppen bestående af hydrogen og alkyl der er usubstitueret eller substitueret med én eller flere substituenten uafhængigt valgt fra gruppen bestående af cycloalkyl, heterocyclyl, aryl, og heteroaryl;


- 15 R^4 er valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, halo, hydroxy, cyano, $-S(O)_n-N(R^8)-R^8$ hvor n er 0, 1, eller 2, $-NR^8C(O)NR^8R^8$, og $-X^1R^8$ hvor X^1 er oxygen, $-S(O)_n-$ eller $-NR^9-$ hvor n er 0, 1, eller 2,;

- 20 hver R^8 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, cycloalkyl, substitueret cycloalkyl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl forudsat at når X^1 er $-SO-$ eller $-SO_2-$, så er R^8 ikke hydrogen; og

hver R^9 er valgt fra gruppen bestående af hydrogen, alkyl, og aryl.


25

15. Fremgangsmåden ifølge krav 11 til fremstilling af en forbindelse med formel VID eller en stereoisomer eller blanding af stereoisomerer deraf:




omfattende trinnene at:


a) kontakte en forbindelse med formel IID med en forbindelse med formel IIIA




under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel ID:




10 b) kontakte en forbindelse med formel ID med en forbindelse med formel VA



under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel IVD:




c) eventuelt omdanne en forbindelse med formel VIID:



under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel IVD; og

5 d) omdanne en forbindelse med formel IVD under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel VID; og eventuelt

e) kontakte en forbindelse med formel VID med glycin under reaktionsbetingelser tilstrækkelige til at fremstille en forbindelse med formel XD:



10

eller en stereoisomer eller blanding af stereoisomerer deraf;
hvor

R² er valgt fra gruppen bestående af hydrogen og alkyl der er usubstitueret eller substitueret med én eller flere substituenten uafhængigt valgt fra
15 gruppen bestående af cycloalkyl, heterocyclyl, aryl, og heteroaryl;

R³ er valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, halo, hydroxy, cyano, -S(O)_n-N(R⁸)-R⁸ hvor n er 0, 1, eller 2, -NR⁸C(O)NR⁸R⁸, og -X¹R⁸
20 hvor X¹ er oxygen, -S(O)_n- eller -NR⁹- hvor n er 0, 1, eller 2, eller R³, R⁴ sammen med carbonatomet afhængigt deraf, danner cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, eller substitueret heteroaryl;

hver R^8 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, cycloalkyl, substitueret cycloalkyl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl forudsat at når X^1 er $-SO-$ eller $-SO_2-$, så er R^8 ikke hydrogen;
5 og

hver R^9 er valgt fra gruppen bestående af hydrogen, alkyl, og aryl.

16. Fremgangsmåden ifølge krav 14 eller 15, hvor

- (i) R^2 er hydrogen og R^4 er phenoxy; eller
- 10 (ii) R^2 er hydrogen og R^4 er 4-methoxyphenoxy; eller
- (iii) R^2 er hydrogen og R^4 er 3,5-difluorphenoxy.

17. Fremgangsmåden ifølge et hvilket som helst af kravene 11, 12, 14 eller 15, hvor

- 15 (i) reaktionsbetingelserne fra trin a) omfatter en syre, fx iseddikesyre; eller
- (ii) trin a) udføres ved en temperatur større end ca. 30°C , fx ved en temperatur på fra ca. 50°C til ca. 60°C ; eller
- (iii) trin b) udføres ved en temperatur større end ca. 30°C , fx ved en temperatur på ca. 100°C ; eller
- 20 (iv) fremgangsmåden omfatter trin c); eller
- (v) fremgangsmåden omfatter trin c) og reaktionsbetingelserne fra trin c) omfatter en amin, fx morpholin; eller
- (vi) fremgangsmåden omfatter trin c) og trin c) udføres i dichlormethan; eller

(vii) fremgangsmåden omfatter trin c) og trin c) udføres ved en temperatur under ca. 25°C, fx ved en temperatur på fra ca. 0°C til ca. 10°C; eller

(viii) reaktionsbetingelserne fra trin d) omfatter hydrogen; eller

(ix) reaktionsbetingelserne fra trin d) omfatter en base, fx
5 natriumcarbonat; eller

(x) reaktionsbetingelserne fra trin d) omfatter fra ca. 0.5 til ca. 1 molær ækvivalenter natriumcarbonat; eller

(xi) reaktionsbetingelserne fra trin d) omfatter ethylacetat; eller


(xii) reaktionsbetingelserne fra trin d) omfatter en katalysator, fx Pd/C.

10

18. Fremgangsmåden ifølge et hvilket som helst af kravene 1, 2, 11 eller 12 hvor fra ca. 1,1 til ca. 1,5 molær ækvivalenter af forbindelsen med formel III anvendes, eller fremgangsmåden ifølge krav 14 eller 15 hvor fra ca. 1,1 til ca. 1,5
15 molær ækvivalenter af forbindelsen med formel IIIA anvendes.

19. Fremgangsmåden ifølge et hvilket som helst af kravene 4, 5, 11 eller 12 hvor fra ca. 2 til ca. 3 molær ækvivalenter af forbindelsen med formel V anvendes, eller fremgangsmåden ifølge krav 14 eller 15 hvor fra ca. 2 til ca. 3 molær
20 ækvivalenter af forbindelsen med formel VA anvendes.

20. En forbindelse med formel VIII:



VIII

hvor:

25 Z er O, NR¹ eller S;

R^1 er valgt fra gruppen bestående af hydrogen og alkyl;

R^2 er valgt fra gruppen bestående af hydrogen og alkyl der er usubstitueret eller substitueret med én eller flere substituenten uafhængigt valgt fra gruppen bestående af cycloalkyl, heterocyclyl, aryl, og heteroaryl;

5 R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, halo, hydroxy, cyano, $-S(O)_n-N(R^8)-R^8$ hvor n er 0, 1, eller 2, $-NR^8C(O)NR^8R^8$, og $-X^1R^8$ hvor X^1 er oxygen, $-S(O)_n-$ eller $-NR^9-$ hvor n er 10 0, 1, eller 2, eller R^3 , R^4 sammen med carbonatomet bundet dertil, danner cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, eller substitueret heteroaryl;

15 R^5 og R^6 er uafhængigt valgt fra gruppen bestående af hydrogen, halo, alkyl, substitueret alkyl, alkoxy, substitueret alkoxy, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl og $-X^2R^{10}$ hvor X^2 er oxygen, $-S(O)_n-$ eller $-NR^{13}-$ hvor n er 0, 1, eller 2, eller når X^2 er $-NR^{13}-$, så kan R^{13} og R^{10} , sammen med det nitrogenatom til hvilket de er bundet, være forbundet til at danne heterocyclyl eller substitueret heterocyclylgruppe;

R^7 er enten $-N(R^{11})(R^{11})$ eller $-OC(O)R^{12}$;

20 hver R^8 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, cycloalkyl, substitueret cycloalkyl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl forudsat at når X^1 er $-SO-$ eller $-SO_2-$, er R^8 ikke hydrogen;

25 R^9 og R^{13} er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, og aryl;


R^{10} er valgt fra gruppen bestående af alkyl, substitueret alkyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl;

hver R^{11} er uafhængigt valgt fra alkyl, benzyl og aryl, eller to R^{11} sammen med det nitrogenatom til hvilket de er bundet danner en 4-8-leddet heterocyclyl eller en heteroaryl; og

5 hver R^{12} er uafhængigt valgt fra gruppen bestående af alkyl, aryl, heteroaryl, og heterocyclyl;

eller en salt, ester, stereoisomer, eller blanding af stereoisomerer deraf; forudsat at forbindelsen ikke er 1-dimethylaminomethyl-4-hydroxy-7-phenylsulfanylisquinolin-3-carboxylsyre-butylester.

10 **21.** Forbindelsen ifølge krav 20 med formel VIIIA:



VIIIA

hvor:

15 R^2 er valgt fra gruppen bestående af hydrogen og alkyl der er usubstitueret eller substitueret med én eller flere substituent uafhængigt valgt fra gruppen bestående af cycloalkyl, heterocyclyl, aryl, og heteroaryl;

20 R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, halo, hydroxy, cyano, $-S(O)_n-N(R^8)-R^8$ hvor n er 0, 1, eller 2, $-NR^8C(O)NR^8R^8$, og $-X^1R^8$ hvor X^1 er oxygen, $-S(O)_n-$ eller $-NR^9-$ hvor n er 0, 1, eller 2, eller R^3 , R^4 sammen med carbonatomet bundet dertil, danner cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, eller substitueret heteroaryl;

25 R^5 og R^6 er uafhængigt valgt fra gruppen bestående af hydrogen, halo, alkyl, substitueret alkyl, alkoxy, substitueret alkoxy, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl og $-X^2R^{10}$ hvor X^2 er oxygen, $-S(O)_n-$ eller $-NR^{13}-$ hvor n er 0, 1, eller 2, eller når X^2 er $-NR^{13}-$, så kan R^{13} og R^{10} ,

sammen med det nitrogenatom til hvilket de er bundet, være forbundet til at danne heterocyclyl eller substitueret heterocyclylgruppe;

R^7 er enten $-N(R^{11})(R^{11})$ eller $-OC(O)R^{12}$;

5 hver R^8 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, cycloalkyl, substitueret cycloalkyl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl forudsat at når X^1 er $-SO-$ eller $-SO_2-$, så er R^8 ikke hydrogen;

R^9 og R^{13} er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, og aryl;

10 R^{10} er valgt fra gruppen bestående af alkyl, substitueret alkyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl;

15 hver R^{11} er uafhængigt valgt fra alkyl, benzyl og aryl, eller to R^{11} sammen med det nitrogenatom til hvilket de er bundet danner en 4-8-leddet heterocyclyl eller en heteroaryl; og

hver R^{12} er uafhængigt valgt fra gruppen bestående af alkyl, aryl, heteroaryl, og heterocyclyl;

20 eller en salt, ester, stereoisomer, eller blanding af stereoisomerer deraf; forudsat at forbindelsen ikke er 1-dimethylaminomethyl-4-hydroxy-7-phenylsulfanyliisoquinolin-3-carboxylsyre-butylester.

22. Forbindelsen ifølge krav 20 eller krav 21, hvor

(i) R^2 er usubstitueret alkyl; eller

(ii) R^5 og R^6 er hydrogen; eller

25 (iii) R^2 er valgt fra gruppen bestående af alkyl der er usubstitueret eller substitueret med én eller flere substituent uafhængigt valgt fra gruppen bestående af cycloalkyl, heterocyclyl, aryl, og heteroaryl; og R^5 og R^6 er hydrogen;

(iv) R^7 er $-N(R^{11})(R^{11})$ og R^{11} er C_1 til C_4 alkyl; eller

(v) R^7 er $-OC(O)R^{12}$ og R^{12} er C_1 til C_4 alkyl;

(vi) R^2 er alkyl der er usubstitueret eller substitueret med én eller flere substituenten uafhængigt valgt fra gruppen bestående af cycloalkyl, heterocyclyl, aryl, og heteroaryl;

5

R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, halo, hydroxy, cyano, $-S(O)_n-N(R^8)-R^8$ hvor n er 0, 1, eller 2, $-NR^8C(O)NR^8R^8$, og $-X^1R^8$ hvor X^1 er oxygen, $-S(O)_n-$ eller $-NR^9-$ hvor n er 0, 1, eller 2, eller R^3 , R^4 sammen med carbonatomet bundet dertil, danner cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, eller substitueret heteroaryl;

10

R^5 og R^6 er hydrogen;

15

R^7 er $-N(R^{11})(R^{11})$;

hver R^8 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, cycloalkyl, substitueret cycloalkyl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl forudsat at når X^1 er $-SO-$ eller $-SO_2-$, så er R^8 ikke hydrogen;

20

R^9 er valgt fra gruppen bestående af hydrogen, alkyl, og aryl; og

hver R^{11} er uafhængigt valgt fra C_1 til C_4 alkyl og aryl; eller

(vii) R^2 er alkyl der er usubstitueret eller substitueret med én eller flere substituenten uafhængigt valgt fra gruppen bestående af cycloalkyl, heterocyclyl, aryl, og heteroaryl;

25

R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, halo, hydroxy, cyano, $-S(O)_n-N(R^8)-R^8$ hvor n er 0, 1, eller 2,

$-NR^8C(O)NR^8R^8$, og $-X^1R^8$ hvor X^1 er oxygen, $-S(O)_n-$ eller $-NR^9-$ hvor n er 0, 1, eller 2, eller R^3 , R^4 sammen med carbonatomet bundet dertil, danner cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, eller substitueret heteroaryl;

5 R^5 og R^6 er hydrogen;


R^7 er $-OC(O)R^{12}$;

hver R^8 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, cycloalkyl, substitueret cycloalkyl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret
 10 heterocyclyl forudsat at når X^1 er $-SO-$ eller $-SO_2-$, så er R^8 ikke hydrogen;

R^9 er valgt fra gruppen bestående af hydrogen, alkyl, og aryl; og

hver R^{12} er uafhængigt valgt fra gruppen bestående af alkyl, aryl, heteroaryl, og heterocyclyl.

15 **23.** Forbindelse som er 4-hydroxy-7-phenoxyisoquinolin-3-carboxylsyre-methylester (3a):



20 **24.** Fremgangsmåden ifølge et hvilket som helst af kravene 1, 4, eller 11 hvor R^1 er hydrogen.

25. Fremgangsmåden ifølge et hvilket som helst af kravene 1, 2, 4, 5, 8, 9, 11, 12, 14 eller 15 hvor R^2 er hydrogen eller alkyl.

25

26. Fremgangsmåden ifølge et hvilket som helst af kravene 1, 2, 4, 5, 8, 9, 11 eller 12, hvor

(i) R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, halo, hydroxy, cyano, $-S(O)_n-N(R^8)-R^8$, $-NR^8C(O)NR^8R^8$, og $-X^1R^8$;

5 hvor X^1 er oxygen, $-S(O)_n-$, eller $-NR^9-$;

n er 0, 1, eller 2;

hver R^8 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, cycloalkyl, substitueret cycloalkyl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl forudsat at når X^1 er $-SO-$ eller $-SO_2-$, så er R^8 ikke hydrogen; og

10

R^9 er valgt fra gruppen bestående af hydrogen, alkyl, og aryl;

eller R^3 og R^4 sammen med de carbonatomer der er bundet dertil, danner cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, eller substitueret heteroaryl; eller

15

(ii) R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, aryl, heteroaryl, hydroxy, $-S(O)_n-N(R^8)-R^8$, $-NR^8C(O)NR^8R^8$, og $-X^1R^8$; hvor

X^1 er oxygen, $-S(O)_n-$, eller $-NR^9-$;

n er 0, 1, eller 2;

20 R^8 er aryl eller substitueret aryl; og

R^9 er hydrogen, alkyl eller aryl;

eller R^3 og R^4 sammen med de carbonatomer der er bundet dertil, danner cycloalkyl, heterocyclyl, aryl, eller heteroaryl; eller

(iii) R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen og $-X^1R^8$; hvor X^1 er oxygen, og R^8 er aryl eller substitueret aryl; eller

25

(iv) R^5 og R^6 er uafhængigt valgt fra gruppen bestående af hydrogen, halo, alkyl, substitueret alkyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl og $-X^2R^{10}$;

hvor X^2 er oxygen, $-S(O)_n-$, eller $-NR^{13}-$;

5 n er 0, 1, eller 2;

R^{10} er aryl eller substitueret aryl; og

R^{13} er valgt fra gruppen bestående af hydrogen, alkyl, og aryl; eller

(v) R^5 og R^6 er uafhængigt valgt fra gruppen bestående af hydrogen og $-X^2R^{10}$; hvor X^2 er oxygen, og R^{10} er aryl eller substitueret aryl; eller

10 (vi) R^5 og R^6 er hydrogen; eller

(vii) R^2 er hydrogen eller alkyl;

R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, halo, hydroxy, cyano, $-S(O)_n-N(R^8)-R^8$, $-NR^8C(O)NR^8R^8$, og $-X^1R^8$;

15 hvor X^1 er oxygen, $-S(O)_n-$, eller $-NR^9-$;

n er 0, 1, eller 2;

hver R^8 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, cycloalkyl, substitueret cycloalkyl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl forudsat at når X^1 er $-SO-$ eller $-SO_2-$, så er R^8 ikke hydrogen; og

20

R^9 er valgt fra gruppen bestående af hydrogen, alkyl, og aryl;

eller R^3 og R^4 sammen med de carbonatomer der er bundet dertil, danner cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, eller substitueret heteroaryl; og

25

R^5 og R^6 er uafhængigt valgt fra gruppen bestående af hydrogen, halo, alkyl, substitueret alkyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl og $-X^2R^{10}$; hvor
 X^2 er oxygen, $-S(O)_n-$, eller $-NR^{13}-$;

5 n er 0, 1, eller 2;

R^{10} er aryl eller substitueret aryl; og

R^{13} er valgt fra gruppen bestående af hydrogen, alkyl, og aryl; eller

(viii) R^2 er hydrogen eller alkyl;

10 R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, aryl, heteroaryl, hydroxy, $-S(O)_n-N(R^8)-R^8$, $-NR^8C(O)NR^8R^8$, og $-X^1R^8$; hvor

X^1 er oxygen, $-S(O)_n-$, eller $-NR^9-$;

n er 0, 1, eller 2;

R^8 er aryl eller substitueret aryl; og

R^9 er hydrogen, alkyl eller aryl;

15 eller R^3 og R^4 sammen med de carbonatomer der er bundet dertil, danner cycloalkyl, heterocyclyl, aryl, eller heteroaryl; og

R^5 og R^6 er uafhængigt valgt fra gruppen bestående af hydrogen og $-X^2R^{10}$; hvor X^2 er oxygen, og R^{10} er aryl eller substitueret aryl; eller

(ix) R^2 er hydrogen eller alkyl;

20 R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen og $-X^1R^8$; hvor X^1 er oxygen, og R^8 er aryl eller substitueret aryl; og

R^5 og R^6 er hydrogen.

27. Fremgangsmåden ifølge et hvilket som helst af kravene 1, 2, 4, 5, 11 eller 12, hvor

(i) R^{11} er C_1 til C_4 alkyl; eller

(ii) R^{11} er methyl.

5

28. Fremgangsmåden ifølge et hvilket som helst af kravene 4, 5, 8, 9, 11 eller 12, hvor

(i) R^{12} er C_1 til C_4 alkyl; eller

10 (ii) R^{12} er methyl.

29. Fremgangsmåden ifølge krav 7, hvor

(i) R^1 er hydrogen; eller

(ii) R^1 er hydrogen eller alkyl; eller

15 (iii) R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, halo, hydroxy, cyano, $-S(O)_n-N(R^8)-R^8$, $-NR^8C(O)NR^8R^8$, og $-X^1R^8$;

hvor X^1 er oxygen, $-S(O)_n-$, eller $-NR^9-$;

20 n er 0, 1, eller 2;

hver R^8 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, cycloalkyl, substitueret cycloalkyl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl forudsat at når X^1 er $-SO-$ eller $-SO_2-$, så er R^8 ikke hydrogen;

25 og

R^9 er valgt fra gruppen bestående af hydrogen, alkyl, og aryl;

eller R^3 og R^4 sammen med de carbonatomer der er bundet dertil, danner cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, eller substitueret heteroaryl; eller

- 5 (iv) R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, aryl, heteroaryl, hydroxy, $-S(O)_n-N(R^8)-R^8$, $-NR^8C(O)NR^8R^8$, og $-X^1R^8$; hvor

X^1 er oxygen, $-S(O)_n-$, eller $-NR^9-$;

n er 0, 1, eller 2;

R^8 er aryl eller substitueret aryl; og

- 10 R^9 er hydrogen, alkyl eller aryl;

eller R^3 og R^4 sammen med de carbonatomer der er bundet dertil, danner cycloalkyl, heterocyclyl, aryl, eller heteroaryl; eller

(v) R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen og $-X^1R^8$; hvor X^1 er oxygen, og R^8 er aryl eller substitueret aryl; eller

- 15 (vi) R^5 og R^6 er uafhængigt valgt fra gruppen bestående af hydrogen, halo, alkyl, substitueret alkyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl og $-X^2R^{10}$;

hvor X^2 er oxygen, $-S(O)_n-$, eller $-NR^{13}-$;

n er 0, 1, eller 2;

- 20 R^{10} er aryl eller substitueret aryl; og

R^{13} er valgt fra gruppen bestående af hydrogen, alkyl, og aryl; eller

(vii) R^5 og R^6 er uafhængigt valgt fra gruppen bestående af hydrogen og $-X^2R^{10}$; hvor X^2 er oxygen, og R^{10} er aryl eller substitueret aryl; eller

(viii) R^5 og R^6 er hydrogen; eller

(ix) R^2 er hydrogen eller alkyl;

R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl, halo, hydroxy, cyano, $-S(O)_n-N(R^8)-R^8$, $-NR^8C(O)NR^8R^8$, og $-X^1R^8$;
 5 hvor X^1 er oxygen, $-S(O)_n-$, eller $-NR^9-$;

n er 0, 1, eller 2;

hver R^8 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, substitueret alkyl, aryl, substitueret aryl, cycloalkyl, substitueret cycloalkyl, heteroaryl, substitueret heteroaryl, heterocyclyl og substitueret heterocyclyl forudsat at når X^1 er $-SO-$ eller $-SO_2-$, så er R^8 ikke hydrogen;
 10 og

R^9 er valgt fra gruppen bestående af hydrogen, alkyl, og aryl;

eller R^3 og R^4 sammen med de carbonatomer der er bundet dertil, danner cycloalkyl, substitueret cycloalkyl, heterocyclyl, substitueret heterocyclyl, aryl, substitueret aryl, heteroaryl, eller substitueret heteroaryl; og
 15

R^5 og R^6 er uafhængigt valgt fra gruppen bestående af hydrogen, halo, alkyl, substitueret alkyl, aryl, substitueret aryl, heteroaryl, substitueret heteroaryl og $-X^2R^{10}$; w
 20 here X^2 er oxygen, $-S(O)_n-$, eller $-NR^{13}-$;

n er 0, 1, eller 2;

R^{10} er aryl eller substitueret aryl; og

R^{13} er valgt fra gruppen bestående af hydrogen, alkyl, og aryl; eller

(x) R^2 er hydrogen eller alkyl;

R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen, alkyl, aryl, heteroaryl, hydroxy, $-S(O)_n-N(R^8)-R^8$, $-NR^8C(O)NR^8R^8$, og $-X^1R^8$; hvor
 25

X^1 er oxygen, $-S(O)_n-$, eller $-NR^9-$;

n er 0, 1, eller 2;

R^8 er aryl eller substitueret aryl; og

R^9 er hydrogen, alkyl eller aryl;

5 eller R^3 og R^4 sammen med de carbonatomer der er bundet dertil, danner cycloalkyl, heterocyclyl, aryl, eller heteroaryl; og

R^5 og R^6 er uafhængigt valgt fra gruppen bestående af hydrogen og $-X^2R^{10}$; hvor X^2 er oxygen, og R^{10} er aryl eller substitueret aryl; eller

(xi) R^2 er hydrogen eller alkyl;

10 R^3 og R^4 er uafhængigt valgt fra gruppen bestående af hydrogen og $-X^1R^8$; hvor X^1 er oxygen, og R^8 er aryl eller substitueret aryl; og

R^5 og R^6 er hydrogen; eller

(xii) R^{12} er C_1 til C_4 alkyl; eller

(xiii) R^{12} er methyl.